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A B S T R A C T
Background
It is estimated that up to 75% of cancer survivors may experience cognitive impairment as a result of cancer treatment and given the
increasing size of the cancer survivor population, the number of affected people is set to rise considerably in coming years. There is a
need, therefore, to identify effective, non-pharmacological interventions for maintaining cognitive function or ameliorating cognitive
impairment among people with a previous cancer diagnosis.
Objectives
To evaluate the cognitive effects, non-cognitive effects, duration and safety of non-pharmacological interventions among cancer patients
targeted at maintaining cognitive function or ameliorating cognitive impairment as a result of cancer or receipt of systemic cancer
treatment (i.e. chemotherapy or hormonal therapies in isolation or combination with other treatments).
Search methods
We searched the Cochrane Centre Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PUBMED, Cumulative Index
of Nursing and Allied Health Literature (CINAHL) and PsycINFO databases. We also searched registries of ongoing trials and grey
literature including theses, dissertations and conference proceedings. Searches were conducted for articles published from 1980 to 29
September 2015.
Selection criteria
Randomised controlled trials (RCTs) of non-pharmacological interventions to improve cognitive impairment or to maintain cognitive
functioning among survivors of adult-onset cancers who have completed systemic cancer therapy (in isolation or combination with other
treatments) were eligible. Studies among individuals continuing to receive hormonal therapy were included. We excluded interventions
targeted at cancer survivors with central nervous system (CNS) tumours or metastases, non-melanoma skin cancer or those who had
received cranial radiation or, were from nursing or care home settings. Language restrictions were not applied.
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Data collection and analysis
Author pairs independently screened, selected, extracted data and rated the risk of bias of studies. We were unable to conduct planned
meta-analyses due to heterogeneity in the type of interventions and outcomes, with the exception of compensatory strategy training
interventions for which we pooled data for mental and physical well-being outcomes. We report a narrative synthesis of intervention
effectiveness for other outcomes.
Main results
Five RCTs describing six interventions (comprising a total of 235 participants) met the eligibility criteria for the review. Two trials
of computer-assisted cognitive training interventions (n = 100), two of compensatory strategy training interventions (n = 95), one of
meditation (n = 47) and one of physical activity intervention (n = 19) were identified. Each study focused on breast cancer survivors.
All five studies were rated as having a high risk of bias. Data for our primary outcome of interest, cognitive function were not
amenable to being pooled statistically. Cognitive training demonstrated beneficial effects on objectively assessed cognitive function
(including processing speed, executive functions, cognitive flexibility, language, delayed- and immediate-memory), subjectively reported
cognitive function and mental well-being. Compensatory strategy training demonstrated improvements on objectively assessed delayed-
, immediate- and verbal-memory, self-reported cognitive function and spiritual quality of life (QoL). The meta-analyses of two RCTs
(95 participants) did not show a beneficial effect from compensatory strategy training on physical well-being immediately (standardised
mean difference (SMD) 0.12, 95% confidence interval (CI) -0.59 to 0.83; I2= 67%) or two months post-intervention (SMD - 0.21,
95% CI -0.89 to 0.47; I2 = 63%) or on mental well-being two months post-intervention (SMD -0.38, 95% CI -1.10 to 0.34; I2 =
67%). Lower mental well-being immediately post-intervention appeared to be observed in patients who received compensatory strategy
training compared to wait-list controls (SMD -0.57, 95% CI -0.98 to -0.16; I2 = 0%). We assessed the assembled studies using GRADE
for physical and mental health outcomes and this evidence was rated to be low quality and, therefore findings should be interpreted
with caution. Evidence for physical activity and meditation interventions on cognitive outcomes is unclear.
Authors’ conclusions
Overall, the, albeit low-quality evidence may be interpreted to suggest that non-pharmacological interventions may have the potential
to reduce the risk of, or ameliorate, cognitive impairment following systemic cancer treatment. Larger, multi-site studies including an
appropriate, active attentional control group, as well as consideration of functional outcomes (e.g. activities of daily living) are required
in order to come to firmer conclusions about the benefits or otherwise of this intervention approach. There is also a need to conduct
research into cognitive impairment among cancer patient groups other than women with breast cancer.
P L A I N L A N G U A G E S U M M A R Y
Interventions for cognitive impairment due to non-localised cancer treatment such as chemotherapy or hormonal therapy
The issue
An increasing number of people are surviving and living longer with cancer due to earlier diagnosis, better treatments and an aging
population. In turn, there is an increasing number of people with long-term or long-lasting effects of cancer and its treatment. For
example, up to seven in 10 cancer survivors experience changes in ability regarding memory, learning new things, concentrating,
planning and making decisions about their everyday life, as a result of cancer treatment. This is known as cognitive impairment and
has a significant impact on the daily activities of cancer survivors. These changes may be caused by non-localised, systemic cancer
treatment, such as chemotherapy and is often called ’chemo-fog’ or ’chemobrain’.
The aim of the review
We reviewed studies that have tested interventions intended to improve cognitive impairment or to maintain cognitive function among
people who have been treated with systemic cancer treatments.
What are the main findings?
We identified five eligible studies that described six interventions. These included two studies of computerised cognitive skills practice,
two cognitive coping skills training programmes, one meditation intervention and one exercise intervention. All five studies included
a total of 235 women who had been treated for breast cancer. The findings suggest that cognitive skills practice and cognitive coping
skills training may be useful in improving patient reports and formal assessments of cognition, as well as quality of life. There was
insufficient evidence to know if meditation and exercise interventions had any effect on cognition.
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What is the quality of the evidence?
The quality of the evidence was low. There were problems with study designs and, so, we need to be cautious about our conclusions.
What are the conclusions?
There is not enough good quality evidence to know if any interventions improve cognitive impairment ormaintain cognitive functioning
among people who have received systemic treatment for cancer. There are several ongoing trials in the field, which may provide the
necessary evidence in the future.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Compensatory strategy training compared with wait- list controls for cognitive impairment due to systemic cancer treatment
Patient or population: Cancer pat ients with cognit ive impairment due to systemic cancer treatment
Intervention: Compensatory Strategy Training
Comparison: Wait-list control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Compensatory strat-
egy training
Physical well-being
SF-36 Physical Compo-
nent Summary Score 0
to 100, higher scores in-
dicate higher levels of
physical well-being
Immediately post-inter-
vent ion
The mean physical well-
being in the control
group is
43.1 points1
The mean physical well-
being in the interven-
t ion groups was 1.16
points higher
(5.72 points lower to 8.
05 points higher)
95
(2)
⊕⊕©©
lowa,b
Physical well-being
SF-36 Physical Compo-
nent Summary Score 0-
100, higher scores in-
dicate higher levels of
physical well-being
Two-months post-inter-
vent ion
The mean physical well-
being in the control
group is
43.1 points
The mean physical well-
being in the interven-
t ion groups was 2.04
points lower
(8.63 points lower to 4.
56 points higher)
95
(2)
⊕⊕©©
lowa,b
Psychological well-be-
ing
SF-36 Mental Compo-
nent Summary Score 0
The mean psycholog-
ical well-being in the
control group is
50.5 points1
The mean psychologi-
cal well-being in the in-
tervent ion groups was
5.13 points lower
95
(2)
⊕⊕©©
lowa,b
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to 100, higher scores in-
dicate higher levels of
physical well-being
Immediately post-inter-
vent ion
(8.82 points lower to 1.
44 points higher)
Psychological well-be-
ing
SF-36 Mental Compo-
nent Summary Score 0
to 100, higher scores in-
dicate higher levels of
physical well-being
Two-months post-inter-
vent ion
The mean psycholog-
ical well-being in the
control group is
50.5 points
The mean psychologi-
cal well-being in the in-
tervent ion groups was
3.42 points lower
(9.90 points lower to 3.
06 points higher)
95
(2)
⊕⊕©©
lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
aRisk of Bias (-1): One of the studies did not undertake intent ion-to-treat analysis and it is not clear if the randomisat ion process was fully blinded
bImprecision(-1): The meta-analyses report wide conf idence intervals
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Control values taken f rom the following reference (Imayama 2013)
Abbreviat ions: SF-36 = Short Form health survey- 36 items
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B A C K G R O U N D
Description of the condition
Over the past few decades, survival rates for cancer have improved
steadily. Cancer patients are living longer following treatment due
to a number of factors. These include earlier detection of their can-
cer and the development and use of effective treatments (Coleman
2011). However, this increased survival means that long-term or
delayed/late effects of cancer treatment are being observed more
frequently among cancer survivors (Treanor 2013).One such long-
term or late effect of cancer treatment is cognitive impairment. At
present, there is no consensus about how to define cognitive im-
pairment among cancer patients and there is no common method
of diagnosis (Hess 2007). Changes in cognition are measured and
defined in different ways. For example, patients can self-report
changes or they can be assessed formally using neuropsychologi-
cal test batteries to capture changes in cognition objectively. Ob-
jective tests are the gold standard method of assessment. Change
in terms of impaired functioning may be defined in several ways
and at different levels of severity, for example, one standard de-
viation (SD) change in scores from a previous test, or 1.5 or 2
SD difference in scores from an appropriate comparison group or
population norms (Wefel 2011). Cognitive impairment caused by
cancer treatment may include a breakdown or change in cogni-
tive processes. Patients may have trouble remembering, learning
new things, concentrating, co-ordinating movements or balance,
making decisions that affect their everyday life; they may expe-
rience problems with the management or control system in the
brain, also known as executive functioning (Nelson 2007). Neu-
roimaging studies among treated cancer patients have found struc-
tural changes and activity reduction in areas of the brain (includ-
ing prefrontal/frontal cortex and temporal regions (including hip-
pocampus/parahippocampus)) used for cognitive functions such
as memory and executive functioning (Gehring 2012; Scherling
2013; Simó 2013).
It is estimated that up to 75 per cent of cancer survivors may expe-
rience cognitive impairment as a result of cancer treatment (Bower
2008; Ganz 2001; Harrington 2010; Stein 2008; Treanor 2014).
Impairment may be short-term or long-lasting (10 or more years)
(Ahles 2002; Bower 2008; Koppelmans 2012). The proportion of
cancer patients who experience cognitive impairment varies across
studies due to different study designs, treatments received by pa-
tients, treatment status (e.g. currently receiving treatment or post-
treatment), and how cognitive impairment is defined and assessed
(Gehring 2012). Regarding the specific treatments that are associ-
ated with the development of cognitive impairment, a strong asso-
ciation has been identified between chemotherapy and cognitive
impairment.Often, chemotherapy-induced cognitive impairment
is referred to as ’chemo-brain’ or ’chemo-fog’.
Several suggestions have been made for the mechanism by which
chemotherapy induces cognitive impairment. These include the
following:
• damage to neurons or nerve cells (Ahles 2007; Merriman
2013; Nelson 2007; Raffa 2011);
• damage to deoxyribonucleic acid (DNA) structures (Ahles
2007; Conroy 2013; Joshi 2005; Merriman 2013; Nelson 2007;
Vardy 2008);
• induced hormonal changes (Ahles 2007; Bender 2001;
Merriman 2013);
• induced anaemia (Hess 2007; Nelson 2007);
• inflammatory response of the immune system (Ahles 2007;
Ganz 2012; Janelsins 2012a; Merriman 2013; Nelson 2007)
Treatment-related cognitive impairment may not be limited to
chemotherapy. The problem may occur also following hormone
therapies and local therapies such as cranial radiation (Bender
2001; Ganz 2012; Nelson 2007; Nelson 2008; Vodermaier 2009).
The focus of this review is on systemic therapy, so local radio-
therapy is not included. Genetic susceptibility (e.g. presence of
apolipoprotein E (apoE) ǫ4 allele) and level of cognitive reserve
(which is dependent on a combination of educational, occupa-
tional and lifestyle factors) may also be associated with the devel-
opment of treatment-induced cognitive impairment (Ahles 2007;
Ahles 2012; Argyriou2010;Merriman 2013;Nelson2007).Other
factors including symptoms of depression, anxiety, distress and fa-
tigue may contribute to cognitive impairment (Ganz 2012; Hess
2007). Furthermore, studies have demonstrated that cognitive
processes may be impaired prior to receiving treatment (Ganz
2012; Hess 2007) (for example, due to distress experienced at the
time of cancer diagnosis and anxiety about treatment). The evi-
dence is currently unclear as to how treatment-induced cognitive
impairment and cognitive impairment related to normal aging
differ.
Description of the intervention
This review examines the effects of non-pharmacological interven-
tions designed to improve cognitive function or manage cognitive
impairment following receipt of systemic cancer treatments in iso-
lation or in combination with other treatments. Cranial radiation
for central nervous system (CNS) tumours (see Cochrane review
Day 2014) or metastases are not the focus of this review and were
excluded. We undertook a brief scoping review to identify types
of non-pharmacological interventions that have been studied with
the aim of improving cognitive impairment or maintaining cogni-
tive functioning among cancer survivors (see Why it is important
to do this review).
Three main types of interventions were identified and form the
focus of the review.
• Cognitive rehabilitation including cognitive training which
includes repetitive practice of cognitive skills or processes via
structured tasks or activities with the aim of improving cognition
through practice by strengthening neural pathways (Ferguson
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2012; Martin 2011), and compensatory strategy training which
aims to help a patient to manage or cope with their impaired
cognitive functioning by learning techniques such as the use of
mnemonics to aid memory (Gehring 2012).
• Physical activity interventions are hypothesised to work
through improved oxygenation and blood flow to the brain,
leading to improved cerebrovascular functioning (Nelson 2007),
and stress reduction (Ganz 2012). Physical activity interventions
include any form of exercise or physical activity which may or
may not be aerobic in nature, and which may be undertaken for
occupational or recreational purposes.
• Meditative/relaxation-based intervention is defined as a
mental exercise that involves reaching a focused state of mind
and may include breathing and visualisation exercises (Milbury
2013). Meditative/relaxation-based interventions may maintain
cognitive functioning or improve cognitive impairment directly
or indirectly through stress reduction, which may aid regulation
of the immune system, particularly the regulation of cytokine
production (Ganz 2012; Milbury 2013).
Pharmacological treatments of treatment-induced cognitive im-
pairment are not eligible for this review. Two other reviews have
reported on the commonly experienced side effects of pharmaco-
logical interventions as well as their benefits on cognitive func-
tioning (Gehring 2012; Von Ah 2013). Interventions which in-
clude herbal compounds (e.g. gingko biloba), diet (e.g. high in
antioxidants) or supplements (e.g. vitamin E) are also not eligi-
ble because they act on physiological processes in a similar man-
ner to pharmacological agents. Previously published reviews in the
area have grouped herbal, dietary and supplement interventions
similarly, within the umbrella of pharmacological interventions
(Fardell 2011).
Why it is important to do this review
Although cancer treatment-induced cognitive impairment is usu-
ally mild to moderate, it exerts a substantial impact on a survivor’s
ability to perform everyday tasks. In general, treatment-induced
cognitive impairmentmay impact on their long-termquality of life
(QoL) and ability to process information to make treatment deci-
sions (Ahles 2002; Ganz 2012; Hess 2007). Impairments in cog-
nitive functioning among younger survivors may impact on their
ability to return to work or education, career progression and ed-
ucational attainment (Nelson 2007). Older cancer survivors may
question the balance of benefits and harms of cancer treatment in
terms of survival gains and their already increased risk of cognitive
impairment due to age (Nelson 2007), as well as the possibility of
deficits in functioning and activities of daily living (Kvale 2009).
The proportion of cancer patients that develop treatment-induced
cognitive impairment varies and it is important to try to identify
characteristics of at-risk patients so that well-informed decisions
can be made about potential treatment-related harms whilst being
mindful of uncertainty about which specific chemotherapy or hor-
monal agents are associated with an increased risk of developing
cognitive impairment (Cheung 2012). Currently, the focus is on
managing treatment-induced cognitive impairment among cancer
patients generally, until specific characteristics and potential risk-
increasing treatments are identified, which might lead to potential
prevention strategies. This review is also important because can-
cer is framed usually as a chronic condition and, as noted above,
the population of cancer survivors is increasing and, therefore, the
number of cancer survivors living with treatment-induced cogni-
tive impairment is rising.
Several published reviews of interventions (Fardell 2011; Gehring
2012;Hines 2014; VonAh2011; VonAh2013) and epidemiology
(Craig 2014; Janelsins 2014; McDougall 2014) for cancer-related
cognitive impairment among non-CNS tumour sites have limi-
tations due to study selection, data extraction or methodological
quality appraisal, or the extent of their search in multidisciplinary
databases and grey literature. Moreover, these earlier reviews were
limited to studies reported in English.We conducted a scoping ex-
ercise to inform the planning of our review and found that there are
several new studies in this field that were not included in existing
reviews. The growing number of studies of non-pharmacological
interventions for treatment-induced cognitive impairment merits
rigorous and systematic attention. Given the prevalence of this
condition and the possible preference by cancer survivors for non-
invasive, non-pharmacological methods of management or alle-
viation of cognitive dysfunction, it is important to systematically
review published and unpublished evidence (with no restrictions
by language) on the effects of non-pharmacological interventions
to prevent or ameliorate cognitive impairment following chemo-
therapy in order to inform clinical and individual decision-mak-
ing. Indeed, findings from a review of qualitative studies of can-
cer survivors with cognitive impairment report that already many
individuals may use some of the strategies that form the basis of
behavioural interventions (Myers 2013).
O B J E C T I V E S
The primary objective of this review is to evaluate the cognitive
effects, non-cognitive effects, duration and safety of non-pharma-
cological interventions among cancer patients targeted at main-
taining cognitive function or ameliorating cognitive impairment
as a result of cancer or receipt of systemic cancer treatment (i.e.
chemotherapy or hormonal therapies in isolation or combination
with other treatments). Although it is expected that non-pharma-
cological interventions will pose minimal risk to patients, we ex-
amined each randomised trial to identify safety as an outcome and
incorporate information on intervention safety where possible.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs). We ex-
cluded non-randomised studies and trials with a quasi-experimen-
tal method of allocation (e.g. alternation).
We contacted trial authors for further information about their
method of randomisation when this was not discernible from the
published report in order to decide whether or not to include their
study.
Types of participants
Inclusion criteria
We included the following types of participants:
• patients diagnosed during adulthood (aged 16 years and
older) with any tumour type, with exceptions noted under
exclusion criteria;
• patients who received previous systemic treatment (i.e.
chemotherapy or hormonal therapies) in isolation or in
combination with other treatments;
• patients who received hormone therapy for prophylactic
purposes following the treatment of their cancer;
• patients from community or clinic settings.
Exclusion criteria
We excluded the following types of participants:
• patients who received treatments such as cranial radiation;
• childhood-onset cancer survivors (aged under 16 years old)
(childhood-specific or age-relevant cognitive functioning and
patient-reported outcome measures to assess outcomes in this
group differ from adult measures (Gross-King 2008)).
• patients who received palliative care (because treatment
pathways and medication regimens differ between palliative and
non-palliative care patients and these differences may influence
intervention adherence (Addington 1995));
• patients with primary or metastatic cancer of the brain or
central nervous system (CNS) (because of the direct impact of
the tumour on the brain and thus cognitive processes (Gehring
2008; Gehring 2010));
• patients with non-melanoma skin cancer (because its
epidemiology and treatment differs significantly from other
cancers);
• patients who received prophylactic cranial radiation
(because a Cochrane Review addressing interventions for
cognitive impairment following cranial radiation is currently
registered and the protocol is under development);
• patients from nursing or care home settings (because of the
likelihood of co-morbid dementia or related conditions).
We planned to consider studies which had included both survivors
of childhood-onset and adult-onset cancers if it was possible to
extract data relating specifically to the subgroup of adult-onset
cancer survivors. However, no studies of this kind were identified.
Types of interventions
We considered studies for inclusion in the review if they used non-
pharmacological interventions (including cognitive rehabilitation,
physical activity and meditative/relaxation activities) in order to
maintain cognitive function or improve cognitive impairment in
patients treated with systemic therapies for cancer. We included
multi-component interventions that had a pharmacological ele-
ment only if the major focus was on the non-pharmacological in-
tervention.
Regarding control groups, we included studies with a ’no treat-
ment’ or ’usual care’ group. We planned to include studies which
included both an ’active’ control group as well as a no treatment
group and to use only data from the no treatment control group in
comparison to the intervention group. However, no such studies
were identified.
We did not apply any exclusion criteria regarding aspects of the
intervention such as the duration, frequency of sessions or mode
of delivery (e.g. face-to-face, computer- or web-based and whether
they were delivered on an individual or group basis), but we
planned to discuss differences in these features whenmaking com-
parisons between studies included in the review, if a sufficient num-
ber of studies were identified. We included interventions based at
home or in the community, in clinics or hospitals or, in research
or controlled experimental ’laboratory’ settings.
Types of outcome measures
Primary outcomes
• ’Objective’ cognitive functioning measured using a
validated, standardised test e.g. Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS)
• ’Subjective’ cognitive functioning measured using a
validated, self-report measure e.g. Functional Assessment of
Cancer Treatment-Cognition Function Scale (FACT-Cog)
Secondary outcomes
• Quality of life (QoL) including health-related quality of
life, well-being and daily functioning measured using a validated,
self-report measure e.g. Short-Form Health Survey (SF-36)
• Mood-related outcomes including distress, depression or
anxiety, using a validated, self-report measure e.g. Depression
Anxiety Stress Scale (DASS)
• Fatigue measured using a validated, self-report measure e.g.
Functional Assessment of Cancer Treatment-Fatigue Scale
(FACT-F)
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• Sleep disturbance measured using a validated, self-report
measure e.g. Medical Outcomes Study-Sleep Scale (MOS-Sleep)
• Adherence, assessed as an outcome to identify the extent to
which patients follow the allocated intervention
◦ We planned to use adherence in sensitivity analyses or
as part of the ’Risk of bias’ assessment (for example, we planned
to compare trials with at least 80% of patients assessed at end-
point compared to trials with less than 80% of patients assessed
at end-point). However, an insufficient number of studies were
identified in order to undertake a sensitivity analysis
• Adverse effects e.g. injury in physical activity interventions
• Treatment satisfaction
Search methods for identification of studies
We searched for papers in all languages and planned to arrange
for non-English language papers to be translated, but no non-
English language papers remained following screening of titles and
abstracts.
Electronic searches
We searched the following electronic databases to 29 September
2015:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Cochrane Library);
• MEDLINE (via OvidSP);
• Embase (via OvidSP);
• PsycINFO (via OvidSP);
• CINAHL (via EBSCO);
• PubMed (via National Center for Biotechnology
Information).
We searched the databases for publications from 1980, which is
the year in which studies examining impairments in cognitive
function as a result of cancer treatment began to appear in the
literature (Ahles 2012).The search strategies are available in the
appendices (Appendix 1; Appendix 2; Appendix 3; Appendix 4;
Appendix 5; Appendix 6). We identified all relevant articles in
PubMed (where available) and used the ’related articles’ feature
and performed further searches for newly published articles which
may not have been identified from the main database search.
Searching other resources
Unpublished and grey literature
We searched the following sources for ongoing trials:
• metaRegister of Controlled Trials (mRCT) (http://
www.controlled-trials.com/mrct/);
• Physician Data Query by the National Cancer Institute (
http://www.cancer.gov/cancertopics/pdq),
• ClinicalTrials.gov (http://clinicaltrials.gov/);
• National Cancer Institute’s List of Cancer Clinical Trials (
http://www.cancer.gov/clinicaltrials);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/).
We asked the principal investigators of any identified unpub-
lished trials for relevant data. We sought information about trials
from major co-operative groups active in this area. We identified
conference proceedings and abstracts through ZETOC (http://
zetoc.mimas.ac.uk) andWorldCat Dissertations. Where available,
we would have included data in the review from any ongoing trials
(whilst noting that results may change as the trial progresses).
Handsearching
We checked or handsearched the following sources:
• citation lists of eligible studies (Horsley 2011);
• citation lists of previous reviews of interventions for
cognitive impairment following cancer;
• papers which cited included studies;
• publications by experts in the field.
We searched websites for relevant conference reports from the
following sources (from 1980 to 2014):
• International Cognition and Cancer Task Force (ICCTF);
• International Neuropsychological Society;
• British Journal of Cancer;
• British Cancer Research Meeting;
• Annual Meeting of European Society of Medical Oncology;
• Annual Meeting of the American Society of Clinical
Oncology;
• Other relevant conference proceedings identified through
Web of Science.
Data collection and analysis
Selection of studies
One review author (CT) downloaded all titles and abstracts re-
trieved by electronic searching to a reference manager software
package and removed any duplicates. Pairs of review authors (CT
and MD, CT and RON and CC and UM) examined the remain-
ing references independently by title and abstract first, followed by
full-text articles. We excluded studies which clearly did not meet
the inclusion criteria and obtained copies of the full text of po-
tentially relevant references cited within these articles. The paired
review authors (noted above) independently assessed the eligibil-
ity of retrieved articles. Disagreements were resolved by discussion
between the two review authors or if necessary by an additional
review author (MJC). We documented the reasons for exclusion.
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Data extraction and management
We extracted the following data from included studies.
• Authors, year of publication and journal citation (including
language)
• Country
• Setting
• Inclusion and exclusion criteria
• Study design, methodology
• Study population:
◦ total number randomised
◦ age
◦ sex/gender
◦ co-morbidities
◦ cancer site
◦ stage (the International Federation of Gynecology and
Obstetrics staging system)
◦ grade
◦ treatment history
◦ education
◦ socio-economic status
◦ cognitive status at baseline
• Intervention details:
◦ definition/details
◦ intervention components (we created a taxonomy of
intervention components by extracting data on the specific
components involved in each intervention)
◦ safety
◦ adverse effects
• Comparison:
◦ definition/details
• Risk of bias in study (seeAssessment of risk of bias in
included studies)
• Duration of follow-up
• Outcomes:
◦ we extracted the definition and unit of measurement
(if relevant) for each outcome
◦ we extracted information about the measures and their
properties including domains of cognition used to assess
outcomes
◦ we recorded variables and their adjustment in the
analyses when calculating adjusted estimates
• Results:
◦ number of participants allocated to each intervention
group and control group, the total number analysed for each
outcome, and the proportion of participants in the intervention
and control groups that were lost to follow-up and their reasons
We planned to extract results as follows:
• Continuous outcomes (e.g. cognitive functioning measures)
◦ baseline value and final mean value and standard
deviation of the outcome of interest and the number of patients
assessed at end-point in each group at end of follow-up in order
to estimate the mean between-group difference and standard
error.
• Dichotomous outcomes (e.g. adverse events):
◦ hazard ratio (HR) or, if a HR was unavailable the
number of patients in each treatment group that experienced the
outcome of interest and the number of patients assessed for that
outcome in order to calculate a risk ratio (RR). However, no
dichotomous outcomes were reported in any of the included
studies.
We extracted reported unadjusted and adjusted statistics. Our data
analysis was guided by an intention-to-treat approach in which
participants were analysed according to the groups to which they
had been randomly assigned. We noted the time points at which
outcomes were collected and reported.
Assessment of risk of bias in included studies
We assessed risk of bias in included studies using theCochrane tool
(Higgins 2011). We used RevMan to facilitate the presentation of
our findings from the ’Risk of bias’ assessment (Review Manager
2014). This assessment addressed selection bias, performance bias,
detection bias, attrition bias, reporting bias and other potential
sources of bias including comparability of intervention and control
group cognitive function scores at baseline, as well as the validity
and reliability of cognitive function assessment measures.
We used the following items to assess risk of bias:
• random sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants (performance bias);
• blinding of personnel (performance bias);
• blinding of assessment of outcomes (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias).
Three review authors worked in pairs (CT and RON or CT and
UM) to apply the ’Risk of bias’ tool independently. Any differences
were resolved by discussion or with an additional review author
(MD). We summarised results in a ’Risk of bias’ graph. We had
planned to examine funnel plots corresponding to meta-analysis
of cognitive functioning (the primary outcome) to assess the po-
tential for small-study effects such as publication bias if sufficient
studies were included (e.g. more than 10), but too few studies were
identified.
An overall risk of bias score was given to each study based on the
following criteria.
• Low: all criteria scored as low risk of bias
• Moderate: one or two criteria unclear or high risk of bias
• High: more than two criteria scored unclear or high risk of
bias
Measures of treatment effect
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The majority of outcome variables were continuous and the stud-
ies used a variety of tools to assess cognitive function. We used
the standardised mean difference (SMD) to compare treatment
groups when different scales were used. Neuropsychological tests
do not provide a global score of cognitive function usually, so tri-
als tended to include multiple cognitive function test scores. We
planned to conduct meta-analyses based on similar cognitive func-
tion domains measured across trials (e.g. executive functioning), if
appropriate datawere available from a sufficient number of trials of
similar interventions, but few studies were identified. Therefore,
we only undertook small meta-analyses comparing compensatory
strategy training interventions when comparable outcomes were
reported (e.g. physical and mental well-being). We planned to use
the risk ratio (RR) with 95% confidence intervals (CIs) to com-
pare treatment groups for dichotomous outcomes such as adverse
events, but, dichotomous outcomes were not reported in any of
the studies.
Dealing with missing data
Wedidnot imputemissing outcomedata for cognitive functioning
(the primary outcome) or for any of the secondary outcomes, but
imputed data had been reported in two studies (Ferguson 2012;
Milbury 2013). We asked trial authors for data on outcomes for
participants whose data were not reported.
Assessment of heterogeneity
We estimated heterogeneity using the I2 statistic within the meta-
analysis of two trials that we conducted.
Data synthesis
It was not possible to implement all the plans in our protocol be-
cause of an insufficient number of studies and the low method-
ological quality of the studies. We were not in a position to address
each intervention type or category (e.g. cognitive rehabilitation,
physical activity and relaxation/meditative) in separate meta-anal-
yses, pool results of studies in meta-analyses using the Cochrane
statistical software, (Review Manager 2014), or in trials with mul-
tiple treatment groups, divide the ’shared’ comparison group into
a number of treatment groups and treat comparisons between each
treatment group and the split comparison group as independent
comparisons. We used a random-effects model with inverse vari-
ance weighting for the meta-analyses (DerSimonian 1986). ’Sum-
mary of findings’ tables were created in RevMan (ReviewManager
2014) to summarise intervention effects and the quality of evi-
dence using the Cochrane GRADE approach. The GRADE ap-
proach considers quality according to five factors: risk of bias, in-
directness of evidence, inconsistency of evidence, imprecision of
effect estimates and publication bias. The quality of evidence was
downgraded from ’high’ to ’moderate’, ’low’ or ’very low’ quality
according to limitations in each of the aforementioned factors.
Subgroup analysis and investigation of heterogeneity
We did not conduct the planned subgroup analyses for factors
such as age, sex, cancer site, cancer stage, type of intervention,
treatment history, cognitive status prior to study enrolment and
duration of intervention because so few studies were identified.
Sensitivity analysis
Similarly, we did not perform sensitivity analyses (by, for example,
re-running analyses without studies deemed to have a high risk of
bias) because of the small number of included studies.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies
Results of the search
Electronic search
A total of 13,618 titles were identified from the electronic searches
(Figure 1). Following removal of duplicate titles, 8144 titles re-
mained. Screening of titles resulted in the exclusion of 7889 pa-
pers. The remaining 255 abstracts were examined for inclusion
and 215 of these were excluded. Forty full-text papers were ob-
tained and fully screened for eligibility in the review. Four of these
studies met our review’s eligibility criteria.
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Figure 1. Study flow diagram.
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Grey literature and unpublished sources
Sixty-two potentially relevant studies were identified from unpub-
lished and grey literature sources. One study was included, for
which, a published conference poster was available.
Other sources
Three additional potentially relevant studies were identified from
the citation lists of included papers but were excluded. No further
studies were identified from papers which cited the included stud-
ies or related articles identified using PubMed.
Included studies
A total of five studies describing six interventions were included in
the review. One study (Von Ah 2012) included two intervention
groups and a shared wait-list control group; participants had an
equal chance of being randomised into one of the three groups.
Three studies (Ferguson 2012; Kesler 2013; Von Ah 2012) tested
four cognitive rehabilitation interventions including two cognitive
training interventions (Kesler 2013; Von Ah 2012), and two com-
pensatory strategy training interventions (Ferguson 2012; Von Ah
2012). A fourth study tested the feasibility of Tibetan SoundMed-
itation on improving cognitive and non-cognitive outcomes. The
fifth study (Campbell 2014) tested the effectiveness of aerobic ex-
ercise on improving cognitive outcomes.
In total, 235 participants were recruited in all five studies and ran-
domised to an intervention group or to a wait-list control group.
The wait-list control groups received standard care during the
study and were offered the intervention at the end of the study
period. All five studies recruited women who had survived breast
cancer. The studies were conducted in two countries: four in the
US (Ferguson 2012; Kesler 2013; Milbury 2013; Von Ah 2012)
and, one in Canada (Campbell 2014). Four studies were published
in peer-reviewed scientific journals (Ferguson 2012; Kesler 2013;
Milbury 2013; Von Ah 2012), and Campbell 2014 was presented
at a conference. All studies were reported in English.
Ferguson 2012 tested an eight-week cognitive behavioural therapy
(CBT)-based Memory Attention Adaptation Training (MAAT)
intervention which targeted improvement of memory and atten-
tion. The study enrolled women with stages I to IIIa breast cancer
who had completed chemotherapy at least 18-months previously
and who self-reported cognitive changes since treatment. The in-
tervention was delivered face-to-face (with telephone contact be-
tween visits) by a clinical health psychologist. MAAT incorpo-
rated education, self-awareness training, self-regulation training
(including relaxation) and cognitive compensatory strategy train-
ing. This study was underpowered and linear interpolation meth-
ods were used to account for missing data in order to undertake
an intention-to-treat analysis. ANCOVAmodels were undertaken
controlling for education and IQ to test for intervention effects on
objective cognitive outcomes (verbal memory, speed of process-
ing), self-reported cognitive function and quality of life (QoL).
Unexpectedly, theMAAT intervention targeting attention did not
include an objective assessment of attention.
Von Ah 2012 examined the effects of a computerised cognitive
training intervention named ’Insight’ and a compensatory strategy
training intervention named ’ACTIVE’, which targeted memory
compared towait-list controls. The interventions involved 10 one-
hour sessions delivered in a group setting by a trained interven-
tionist over a six-week period. This study did not specify the stage
of cancer but required their participants to be disease-free and
treated for primary, non-metastatic breast cancer and have com-
pleted chemotherapy at least one year previously. The Insight pro-
gramme is commercially available, the version adapted for use in
this trial targeted executive functions. The ACTIVE intervention
included sessions on compensatory strategy training for memory
and strategy practice to enhance self-efficacy. The authors con-
ducted general linear mixed models to assess differences between
intervention and control groups using age, education, between-
group treatment effects, within-group time effects and baseline
values for each respective outcome as covariates.
Kesler 2013 reported the results of a 12-week, home-based, com-
mercially-available, computerised cognitive training intervention
targeting executive functions among females with stages I to IIIa
breast cancer. Participants were recruited irrespective of cognitive
function status but had to have completed chemotherapy at least
18 months previously. Women allocated to the intervention re-
ceived written instructions and weekly telephone/email contact
for 48 sessions. Using ANCOVA models, a number of covariates
including baseline cognitive flexibility scores, age, level of educa-
tion, radiation, distress scores, hormonal therapy and time since
chemotherapy were initially added to the models to assess the ef-
fects of the intervention on executive functions; however, the co-
variates were later removed as they did not significantly impact
upon the relationship between cognitive training and executive
functions. The primary outcome of interest in the studywas cogni-
tive flexibility measured by the Wisconsin Card Sorting Task and
a Bonferroni correction was applied for all additional ANCOVA
models to control for the effects of multiple testing. The authors
also calculated corrected effect sizes to counteract potential prac-
tice effects of the neuropsychological test measures by subtracting
the within-group control group effect size from that of the inter-
vention group.
Milbury 2013 assessed the feasibility and effectiveness of Tibetan
Sound Meditation on cognitive function (self-reported, visuo-
motor co-ordination, processing speed, attention, working mem-
ory, verbal fluency and memory), and non-cognitive outcomes
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(fatigue, depression, sleep disturbances, spiritual well-being and
health-related quality of life) among women with stages I to IIIa
breast cancer who were treated with chemotherapy up to five years
previously. Each participant was eligible if they self-reported cog-
nitive impairment using a partial version of the Functional Assess-
ment of Cancer Therapy-Cognitive functioning sub scale (FACT-
Cog). Tibetan SoundMeditation is ameditative practice involving
breathing techniques, visualisation, meditative sounds and cog-
nitive tasks. The 6-week intervention was delivered by a trained
meditation instructor to between one and three participants who
were provided also with a CD and written instructions to practice
at home. Objective assessments of cognition were not undertaken
immediately post-intervention in order to counteract practice ef-
fects. Statistical analyses involved between-group ANOVAmodels
controlling for baseline values of each respective outcome. There
were limitations to this study as a formal sample size calculation
was not reported in the paper and the authors stated that the
study was statistically under-powered which may account for the
absence of significant intervention effects (Milbury 2013). This
intervention is currently being evaluated in a larger randomised
controlled trial (RCT) including neuro-imaging techniques as an
additional objective measure of cognition (Cohen 2014).
In a Canadian proof of concept study, 19 women who had com-
pleted chemotherapy for early-stage (I-IIIa) breast cancer at least
three months previously were allocated to 24 weeks of aerobic
exercise (n = 10) or to a delayed exercise control group (n = 9)
(Campbell 2014). To be eligible, participants had to self-report
changes in cognitive function which had persisted since treatment.
Researchers undertook paired t-tests and ANCOVA models con-
trolling for baseline scores to observe changes in self-reported cog-
nitive function, objectively assessed memory, learning, verbal flu-
ency, processing speed and executive functions over time. The 24-
week long intervention (including twice-weekly contacts) involved
supervised and independent aerobic exercise sessions but it is not
clear if this was delivered face-to-face or in a group setting and
the type of professional involved in the intervention was not de-
scribed. The results of this study were reported in a conference
poster and have not yet been published in a peer-reviewed journal
(as of August 2015). Correspondence was made with the author
to obtain further information regarding, for example, randomisa-
tion.
Where necessary, study authors were contacted to provide data
in a different format than was reported in the original papers.
For example, Von Ah 2012 reported effect sizes (including 95%
confidence intervals) for composite scores of their objective mea-
sures, but did not report the means and standard deviations on
composite scores or individual measures at post-intervention time
points that were required in order to undertake a meta-analysis.
Non-imputed values of outcomes were requested for one study
(Ferguson 2012). At the time of writing of this review, requests for
alternatively presented data were unfulfilled. Therefore, findings
as reported in the original papers were included in this review.
Components and techniques of interventions
Two review authors (CT andMD) developed a taxonomy of simi-
lar and unique intervention components and techniques across the
six interventions. A standardised pro forma was created, guided
by the COMPASS criteria (Hodges 2011) for defining psycholog-
ical interventions and the Behaviour Change Techniques (BCT)
taxonomy (Michie 2013). Two techniques were common across
all six interventions: instruction on how to perform the behaviour
and demonstration (Campbell 2014; Ferguson 2012; Kesler 2013;
Milbury 2013; Von Ah 2012). Behavioural practice/rehearsal
was common to five interventions (Ferguson 2012; Kesler 2013;
Milbury 2013; VonAh2012). Several techniques were common to
three interventions: social support (unspecified) due to the group
setting delivery of the intervention (Kesler 2013; Milbury 2013;
Von Ah 2012), feedback on behaviour (Ferguson 2012; Kesler
2013; Von Ah 2012), generalisation of a target behaviour from a
supervised setting to everyday settings (Campbell 2014; Ferguson
2012; Milbury 2013), and graded tasks of increasing difficulty
(Campbell 2014; Kesler 2013; Von Ah 2012). Two interventions,
CBTMAAT compensatory training (Ferguson 2012) and Tibetan
Sound Meditation (Milbury 2013) included reducing negative
emotions as a technique. Prompts/cues were used in two interven-
tions (Ferguson 2012; Kesler 2013) via telephone contact from a
member of the research team.
The remaining techniques were unique to intervention types. The
physical activity intervention included the unique technique of
goal setting as each individual was expected to reach the target
exercise prescription by week eight of the intervention (Campbell
2014), whereas, framing/reframing was a technique unique to
Tibetan Sound Meditation (Milbury 2013). Each compensatory
strategy training intervention comprised the following techniques:
instruction on how to perform- and, demonstration of- the be-
haviour via teaching the participants compensatory strategies
and; behavioural practice/rehearsal of strategies was encouraged
(Ferguson 2012; Von Ah 2012). Other techniques (some of which
were unique) in theCBT-basedMAAT intervention include: feed-
back on behaviour via phone-call to adapt or adjust techniques,
self-monitoring of behaviour whereby participants were encour-
aged to keep a daily planner, information about antecedents of
behaviour and health consequences via education, prompts/cues,
generalisation of target behaviour, reduction of negative emo-
tions via relaxation, mental rehearsal of successful performance
through visualisation and self-talk using verbal rehearsal (Ferguson
2012). Both computerised cognitive training interventions con-
tained common techniques: instruction on how to perform the
behaviour, demonstration of how to perform the behaviour, be-
havioural practice/rehearsal, graded tasks, feedback on behaviour
and feedback on outcomes of behaviour (Kesler 2013; Von Ah
2012). The interventions differed in their use of specific tech-
niques: prompts/cues via weekly telephone calls were used in one
study (Kesler 2013), whereas, social support (unspecified) due to
the group setting of intervention delivery was used in the second
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study (Von Ah 2012).
Outcomes
The five studies used a range of different outcome measures.
Three studies only provided participant assessments at one month
(Milbury 2013) and two months (Ferguson 2012; Von Ah 2012)
post-intervention in addition to end-of-intervention assessments.
The other two studies provided participant assessments only at the
end of the intervention (Campbell 2014; Kesler 2013).
Cognitive outcomes
Although there was some overlap in the cognitive functioning do-
mains objectively assessed across the studies, a variety of outcome
measures were used. Some measures were used to measure more
than one cognitive function.
Processing speed
The most commonly measured aspect of cognition was process-
ing speed which was measured in all five studies using: the Wech-
sler Adult Intelligence Scale (WAIS) digit symbol-coding subset
(Ferguson 2012; Milbury 2013); the trail making letter-number,
colour-word interference, colour-word and switching trials of the
Delis-Kaplan Executive Function System (D-KEFS) (Ferguson
2012); three subtests of the Useful Field of View were summed
to calculate a composite processing speed score (Von Ah 2012);
trials A and B and trial A-B difference of the Trail Making Test
(Campbell 2014) and; the WAIS version four symbol search sub-
set (Kesler 2013).
Executive functions
Executive functions were assessed in two studies using the D-
KEFS letter fluency test (Kesler 2013) and the Trail Making Test
(Campbell 2014). Other aspects of Executive function measured
include: working memory, assessed, using the WAIS version four
digit span subtest (Kesler 2013;Milbury 2013); attentionusing the
WAIS digit symbol-coding and digit span subsets (Milbury 2013)
and; cognitive flexibility using the Wisconsin Card Sorting Task
(WCST) (Kesler 2013). Verbal fluency was assessed in two studies
using the Controlled Oral Word Association Test (COWAT) (
Campbell 2014; Milbury 2013). Language was assessed in one
study using the letter fluency subtest of theD-KEFS (Kesler2013).
Memory and learning
Memory and learning were measured in one study using the total
recall, delayed recall, retention and delayed recognition index sub-
tests of the HVLT (Campbell 2014). Visuomotor co-ordination
was assessed by one study using the WAIS digit symbol subset
(Milbury 2013). One study created composite scores for memory
outcomes, composite scores for immediate memory recall were
calculated from the sum of recall trials 1-5, short delay and recog-
nition scores of the RAVLT and immediate recall of the River-
mead Behavioral paragraph Recall Test (RBPRT) (Von Ah 2012).
Composite scores were also calculated for delayed memory recall
from the long-term delay scores of the RAVLT and RBPRT (Von
Ah 2012). Alternate test forms of the CVLT (Ferguson 2012), D-
KEFS and HVLT (Kesler 2013) were used to counteract practice
effects across two studies.
Verbal memory
Verbal memory was assessed in three studies using: summed raw
score of trials 1-5 of the California Verbal Learning Test (CVLT)
version two (Ferguson 2012); trials 1-5, list B and recall of the
Rey Adult Verbal Learning Test (RAVLT) (Milbury 2013) and;
the Hopkin’s Verbal Learning Test (HVLT) (Kesler 2013).
Self-reported cognitive function
All five studies included outcome measures to allow participants
to self-report cognitive functioning. The most commonly used
outcome measure was the FACT-Cog which provides data on
perceived cognitive concerns, perceived cognitive abilities, impact
on QoL and comments from others (Campbell 2014; Milbury
2013; Von Ah 2012). In addition, three further outcomemeasures
of subjective cognitive function were administered; two of which
refer to specific domains of cognition. The additional measures
include: Squire SubjectiveMemoryQuestionnaire (Von Ah2012),
the Behavioral Rating Inventory of Executive Functioning (Kesler
2013) and Multiple Abilities Subjective Questionnaire measuring
five domains of cognition including language, visual perception,
verbal-, visual- memory and attention (Ferguson 2012).
Non-cognitive outcomes
A number of additional outcomes were assessed including quality
of life, depression, anxiety, fatigue and sleep disturbances. Quality
of life was assessed as a secondary outcome in three studies: overall
quality of life scores were provided using the Quality of life-Can-
cer Survivor (QOL-CS) and the Quality of life Index-Cancer ver-
sion (QLI-C) scales (Von Ah 2012); domain scores for physical-,
psychological-, social- and spiritual- quality of life were measured
using the QOL-CS (Ferguson 2012) and spiritual quality of life
only using the Functional Assessment of Cancer Therapy- Spir-
itual sub scale (FACT-Spiritual) (Milbury 2013). Physical- and
mental-health status were assessed using the SF-36 in two studies
(Milbury 2013; Von Ah 2012).
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The Center for Epidemiologial Studies- Depression scale (CES-
D) was used to assess depression in three studies (Ferguson 2012;
Milbury 2013; Von Ah 2012). The Spielberger State Trait Anxiety
Inventory (STAI) was used to assess state anxiety in one study (Von
Ah 2012) and state and trait anxiety in a further study (Ferguson
2012). Fatigue was assessed in two studies using the Functional
Assessment of Cancer Therapy- Fatigue (FACT-F) scale (Von Ah
2012) and Brief Fatigue Inventory (BFI) (Milbury 2013). The
Clinical Assessment of Depression was used to assess psychological
distress including depression, anxiety and cognitive fatigue in one
study (Kesler 2013). Depression, anxiety and fatigue are related to
cognitive function and were unlikely to improve or decline directly
as a result of the cognitive- and compensatory-strategy training
interventions, therefore their assessment was undertaken in order
to control for these factors in analysis in each of the three studies
(Ferguson 2012; Kesler 2013; Von Ah 2012). One study only as-
sessed sleep disturbances using the Pittsburgh SleepQuality Index
(PSQI) (Milbury 2013). The study assessing the effectiveness of
the Tibetan SoundMeditation intervention hypothesised also that
improvements would be observed in quality of life, fatigue, mood
and sleep outcomes for participants (Milbury 2013).
Treatment satisfaction
Three studies assessed satisfaction with the intervention: a study-
specificmeasure was used in one study (Ferguson 2012), theClient
Satisfaction Questionnaire was used in a second study (Von Ah
2012) and a third study required participants to keep a brief eval-
uation of their satisfaction and acceptability of weekly sessions
(Milbury 2013). Acceptability of the intervention was assessed in
an additional study using a study-specific questionnaire (Von Ah
2012).
Safety
Safety issues and adverse effects related to the intervention were
captured in one study only (Kesler 2013). This study reported no
safety issues or adverse events.
Excluded studies
Electronic database search
Thirty-six studies were excluded following examination of the full
text for reasons specified in the Characteristics of excluded studies
table.
Grey literature and unpublished sources
Twenty-two studies were excluded as they were duplicated regis-
tered titles or studies that were identified by the electronic database
search. Contact wasmadewith the Principal Investigator or named
contact researcher when there were insufficient essential details in
a paper.We contacted the researcher to obtain data or an update on
study progress for 40 studies in the grey literature or unpublished
sources. Two replies referred to four additional studies which had
not been identified from other sources. Thereafter, 34 studies were
excluded. Reasons for exclusion are specified in the Characteristics
of excluded studies table.
Regarding the four additional studies that were forwarded to the
review team by three of the contacted authors, three studies were
excluded because the tested interventions were not targeted at
maintaining cognitive function or improving cognitive impair-
ment and the other study was excluded because patients who had
not received systemic treatment were included and we were unable
to separate these patients from those patients who had received
systemic treatment.
Other sources
Three studies were excluded for the following reasons: the inter-
vention was not targeted at improving cognitive impairment or
maintaining cognitive functioning (n = 2) and one study was not
an RCT.
Ongoing studies
Thirteen ongoing studies were identified from trial registries. In-
terventions included: computerised cognitive training (n = 4),
compensatory strategy training (n = 3), physical activity (n = 2),
cognitive training (n = 1) and meditation (n = 1). One trial com-
bined computerised cognitive training and telephone compen-
satory strategy training. A further trial included three interven-
tions encompassing (i) computerised cognitive training, compen-
satory strategy training and relaxation, (ii) active journal writing,
compensatory strategy training and relaxation and (iii) comput-
erised cognitive training only.
Risk of bias in included studies
All five studies were assessed for risk of bias using the ’Risk of bias’
tool provided inRevMan5.3 (ReviewManager 2014).We assessed
the following aspects of the studies: random sequence generation,
allocation concealment, blinding of personnel/participants, blind-
ing of outcome assessors, incomplete outcome data, selective re-
porting, baseline imbalance in cognition scores (both objectively
assessed and subjectively reported) and reliability and validity of
cognition outcome assessments (Figure 2). Overall, studies were
categorised as having a high risk of bias.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
The criteria for the review required studies to be randomised. Each
of the four published studies described how participants were al-
located to groups using computer-generated lists (Ferguson 2012;
Kesler 2013), stratified blocks (Campbell 2014; Von Ah 2012)
and; minimisation (Milbury 2013). Contact with the author of
the unpublished study confirmed that an appropriate random se-
quence generation method was used, namely block randomisation
(Campbell 2014). All studies were scored as having a low risk of
bias relating to random sequence allocation.
Allocation concealment
Four studies described clearly a method of allocation concealment
that was judged to be of low risk of bias. They used computer-
based allocation methods (Ferguson 2012; Kesler 2013), serially
numbered, opaque envelopes (Campbell 2014), or allocation was
undertaken by personnel not involved in the study (Von Ah 2012).
One study did not include sufficient detail to make a judgement,
so we categorised this as having an ’unclear’ risk of bias (Milbury
2013).
Blinding
Performance bias
Due to the nature of the non-pharmacological interventions be-
ing delivered, it was not possible for study participants to be
blinded to group allocation. Therefore, each study was scored as
’low risk’ because it is unlikely that knowledge of group allocation
by researcher or participant would influence outcomes (Campbell
2014; Ferguson 2012; Kesler 2013;Milbury 2013; Von Ah 2012).
Detection bias
Three studies included a clear statement that outcome assessors
were blinded to the group allocation of participants and were
therefore rated as having a ’low’ risk of detection bias (Ferguson
2012; Kesler 2013; Von Ah 2012). Information provided on a
registered trial database about the unpublished study indicated
that outcome assessors were blind to group allocation of study
participants (Campbell 2014). The final study was rated as having
’unclear’ risk of bias because insufficient information about the
outcome assessors was reported (Milbury 2013).
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Incomplete outcome data
Two studies were rated as having a ’low’ risk of attrition bias
because all dropouts were accounted for in both the interven-
tion and control groups and similar reasons for dropout were re-
ported (Campbell 2014; Ferguson 2012). Furthermore, intention-
to-treat analysis was undertaken for three studies (Campbell 2014;
Ferguson 2012; Milbury 2013). Ferguson 2012 used linear inter-
polation methods to impute missing data and did not undertake
sensitivity analysis. Two further studies were rated as ’high’ risk
of bias because they did not undertake intention-to-treat analysis
(Kesler 2013; Von Ah 2012).The final study was rated as ’unclear’
risk of bias as the reason for the dropout of one control group par-
ticipant was not reported and they did not describe their method
of intention-to-treat analysis (Milbury 2013).
Selective reporting
Three studies were rated as having an ’unclear’ risk of bias due to
the failure to report data related to: results of significance testing
in their tables (Milbury 2013), potential confounding variables
in tables (Ferguson 2012) and, means and standard deviations for
individual test measures and composite scores at follow-up time
points (Von Ah 2012). The remaining two studies received a ’low’
risk of bias score because all outcome measure data were reported
in both study text and tables (Campbell 2014; Kesler 2013).
Other potential sources of bias
Other potential sources of bias in this reviewmay result from base-
line imbalances in objectively measured and subjectively reported
cognitive function scores due to the possible failure of the ran-
domisation strategy. Additionally, there is a poor correlation be-
tween objective and subjective assessments of cognitive function
(Green 2005). Often, the cognitive function assessment measures
that are used among cancer patients or survivors have been taken
from other populations e.g. brain trauma, therefore, the use of
potentially unreliable or invalid measures among the cancer pop-
ulation presents a potential risk of bias.
Four (Campbell 2014; Ferguson 2012; Kesler 2013; Milbury
2013) of the five studies were rated as having an ’unclear’ risk
of bias relating to baseline imbalances in objectively assessed cog-
nitive function due to a failure to report the absence (or pres-
ence) of between-group differences in objectively assessed cogni-
tive function at baseline. Only one study (Von Ah 2012) reported
that there were no between-group baseline differences in objec-
tively assessed cognitive function and therefore was rated as having
’low’ risk of bias. Similarly for between-group differences in sub-
jectively reported cognitive function at baseline, only one study
stated clearly whether or not any differences between-groups were
present (Ferguson 2012) and, therefore, was rated as having a ’low’
risk of bias. The other studies were rated as having an ’unclear’ risk
of bias as no clear statement of baseline differences were reported
(Campbell 2014; Kesler 2013; Milbury 2013; Von Ah 2012).
The studies reported infrequently on the reliability and validity
of cognitive function assessment measures, therefore, the risk of
bias was judged to be ’unclear’ for the validity (Ferguson 2012;
Milbury 2013; Von Ah 2012) and reliability (Ferguson 2012;
Milbury 2013; Von Ah 2012) of objective outcome measures and,
the validity (Campbell 2014; Ferguson 2012; Milbury 2013; Von
Ah 2012) and reliability (Campbell 2014; Ferguson 2012; Kesler
2013; Milbury 2013; Von Ah 2012) of subjective outcome mea-
sures. For the validity and reliability of objective outcome mea-
sures, a rating of ’low’ risk of bias was given to two studies be-
cause they reported on the psychometric information related to
themeasures (Kesler 2013) or chose their outcomemeasures based
on the guidelines provided by the ICCTF (Campbell 2014). One
study only provided psychometric information relating to their
outcome measure to assess subjective cognitive function and thus
it was rated as having a ’low’ risk of bias (Kesler 2013).
Effects of interventions
See: Summary of findings for the main comparison
We were able to undertake meta-analyses from two studies (n = 95
participants) comparing physical and mental well-being immedi-
ately after, and 2 months after receipt of compensatory strategy
training.
Computer-assisted cognitive training
The two computer-assisted cognitive training interventions (
Kesler 2013; Von Ah 2012) recruited 100 participants in total.
The studies reported on two overlapping outcomes only: process-
ing speed and self-reported cognitive function.
Objectively assessed cognitive outcomes
Kesler 2013 found a statistically significant improvement in pro-
cessing speed compared to the control group immediately post-in-
tervention (between-group effect size (d) = 0.87, P = 0.009). Sim-
ilarly, Von Ah 2012 found significant improvements in processing
speed compared to the control group immediately post-interven-
tion (d = 0.55, 95% confidence interval (CI) = 0.01 to 1.08, P
value = 0.04) and two -months post-intervention (d = 0.67, 95%
CI = 0.14 to 1.21, P value = 0.016). This study also calculated
reliable improvement scores; a participant demonstrated reliable
improvement if their performance on a measure improved by at
least one standard error of measurement. Compared to 43% and
61% of wait-list controls, 68% and 67% of intervention partic-
ipants demonstrated reliable improvement immediately and two
months post-intervention, respectively.
Significant intervention effects compared to wait-list controls were
found on a number of other objective assessments of cognitive
function immediately post-intervention including executive func-
tions (d = 0.82, P value = 0.003), cognitive flexibility (d = 0.58, P
= 0.008) and language (d = 0.82, P value = 0.003) (Kesler 2013).
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Despite working memory (a domain of executive functions) being
targeted by the Kesler 2013 cognitive training intervention, no
improvement was observed compared to the control group. This
may be due to choice of outcome measure; the digit span test to
measure working memory relies on auditory stimuli which may
not be sufficient to capture the effects of the visually-orientated
intervention on working memory.
Kesler2013 reported a trend towards a beneficial effect of the inter-
vention compared to wait-list controls on verbal memory imme-
diately post-intervention (d = 0.56, P value = 0.07). Although the
intervention did not target specifically verbal memory, the authors
reported that this observed trend may be due to the downstream
effects of improvements in executive functions i.e. the cognitive
domains targeted by the intervention. Transfer effects of the In-
sight intervention were observed on immediate memory recall im-
mediately- (d = 0.75, 95% CI = 0.22 to 1.29, P value = 0.007) and
two months post-intervention (d = 0.82, 95% CI = 0.28 to 1.35,
P value = 0.001), and on delayedmemory recall two months post-
intervention (d = 0.72, 0.18 to 1.26, P value = 0.001) compared to
controls. In terms of reliable improvement, for immediate mem-
ory recall immediately, and two months post-intervention 41%
and 30% of intervention participants demonstrated reliable im-
provement, compared to 10% and 18% of controls, respectively.
Compared to 11% of controls, 33% of intervention participants
demonstrated reliable improvement on delayedmemory recall two
months post-intervention (Von Ah 2012).
Subjective cognitive function
A beneficial effect on self-reported cognitive functioning was
found for the intervention compared to the control group. An im-
provement was not observed on the global composite score of the
BRIEF cognitive functioning measure, but improvements were
observed on two BRIEF subscales including planning and/or or-
ganisation (d = 0.44, P value = 0.02) and task monitoring (d =
0.43, P value = 0.03). It is not clear why the authors calculated
corrected effect sizes for the BRIEF subscales as it is unlikely that
patient-reported outcome measures are at risk of practice effects.
This study did not assess intervention effects at additional time
points so there is no information on the sustainability of interven-
tion effects (Kesler 2013). Compared to wait-list controls, signif-
icant improvements were found for self-reported cognitive func-
tioning on the FACT-Cog (d = 0.55, 95% CI = 0.01 to 1.08) and
SSMQ (d = 0.44, 95% CI =- 0.09 to 0.98) measures immediately
post-intervention, but this effect was not observed at two months
post-intervention.
Non-cognitive outcomes
The Insight intervention also demonstrated beneficial effects on
QoL. There was a beneficial effect of the Insight intervention on
perceived mental health immediately- (d = 0.72, 0.19 to 1.26, P
value = 0.01), and twomonths post-intervention (d = 0.60, 0.07 to
1.13, P value = 0.03) compared to wait-list controls. Nevertheless,
overall quality of life was not improved as a result of the Insight
intervention (Von Ah 2012).
Compensatory strategy training
The two compensatory strategy training interventions (Ferguson
2012; Von Ah 2012) recruited 99 participants in total. Data from
95 participants could be used in the meta-analyses of physical and
mental well-being.The two studiesmeasured twooverlapping out-
comes: processing speed and self-reported cognitive functioning
with findings in similar directions.
Objectively assessed cognitive outcomes
A beneficial effect of the ACTIVE intervention was found with
improvements in immediate- (d = 0.59, 95% CI = 0.05 to 1.13, P
value = 0.036) and delayed- (d = 0.70, 95% CI = 0.16 to 1.24, P
value = 0.013) memory recall compared to controls at two months
post-intervention. This effect was not observed immediately post-
intervention which may reflect findings of similarly published lit-
erature. Thirty-nine per cent and 42%of intervention participants
demonstrated reliable improvement two months post-interven-
tion on immediate- and delayed-memory recall compared to 18%
and 11% of controls, respectively (Von Ah 2012). A significant
group by time interaction (F (2, 76) = 53.16, P value < 0.05) with
significant improvements in verbal memory compared to the wait-
list control group immediately post-intervention (intervention d
=-0.36 versus control d = 0.14, P value < 0.001) and two-months
post-intervention (intervention d = -0.81 versus control d = -0.18,
P value < 0.001) were observed. Many of the MAAT intervention
compensatory strategies involved verbalisation and vocalisations
which may result in this observed effect. Relaxation techniques
may also have contributed to improvements in verbal memory.
No improvements were observed on processing speed as a result
of the ACTIVE (Von Ah 2012) or MAAT intervention (Ferguson
2012).
Subjective cognitive function
Compared to wait-list controls, a beneficial effect of the ACTIVE
interventionwas foundon subjectively reported cognitive function
assessed by the FACT-Cog (d = 0.59, P value = 0.036) and SSMQ (
d = 0.71, P value = 0.012)measures immediately post-intervention
and the FACT-Cog (d = 0.65, P value = 0.021) and SSMQ (d
= 0.84, P value = 0.003) measures two-months post-intervention
(Von Ah 2012). There were no MAAT intervention effects for
self-reported cognitive functioning. The study authors report also
that the FACT-Cog (which was not yet developed at the time of
the study) may be more effective to assess self-reported cognitive
function than the MASQ (Ferguson 2012).
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Non-cognitive outcomes
We considered the analysis of physical and mental health to be
of low quality and that it should be interpreted with caution. See
Summary of findings for the main comparison for more informa-
tion.
When we performedmeta-analyses of these two studies, there was
no apparent effect of compensatory strategy training compared
to wait-list controls on physical well-being immediately post-in-
tervention (standardised mean difference (SMD) 0.12, 95% CI -
0.59 to 0.83), although between-study heterogeneity in this effect
was moderate (I2 = 67%) (Analysis 1.1; Figure 3). Similarly, two-
months post-intervention there was no apparent effect of com-
pensatory strategy training compared to controls on physical well-
being (SMD -0.21, 95% CI -0.89 to 0.47; I2 = 63%) (Analysis
2.1; Figure 4). The effect of compensatory strategy training in-
tervention on psychological well-being post-intervention favoured
the wait-list control group (SMD -0.57, 95% CI -0.98 to -0.16; I
2 = 0%), with no observed between-study heterogeneity (Analysis
1.2; Figure 5). The favourable effect of the compensatory strategy
training intervention on psychological well-being among the con-
trol group was no longer observed two months post-intervention
(SMD -0.38, 95% CI -1.10 to 0.34; I2 = 67%) (Analysis 2.2;
Figure 6).
Figure 3. Forest plot of comparison: 1 Compensatory strategies, outcome: 1.1 Physical well-being at post-
intervention.
Figure 4. Forest plot of comparison: 2 Compensatory strategies versus wait-list control 2-months post-
intervention, outcome: 2.1 Physical well-being.
Figure 5. Forest plot of comparison: 1 Compensatory strategies versus wait-list control immediately post-
intervention, outcome: 1.2 Psychological well-being.
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Figure 6. Forest plot of comparison: 2 Compensatory strategies versus wait-list control 2-months post-
intervention, outcome: 2.2 Psychological well-being.
A significant time by group interaction (F(2,76) = 3.44, P value <
0.05) was observed for the MAAT intervention on spiritual qual-
ity of life compared to wait-list controls immediately post-inter-
vention (intervention d =-0.35 versus control d = 0.14) and two
months post-intervention (intervention d = -0.11 versus control
d = 0.15) in a repeated measures ANCOVA model controlling
for education and IQ. The authors report that this observed im-
provement may reflect participants’ perceived optimism, hopeful-
ness and purpose in life represented by the spiritual QoL items
(Ferguson 2012).
Meditation/relaxation intervention
The trial of Tibetan Sound Meditation intervention found a non-
statistically significant beneficial effect on processing speed (d =
0.25, P value = 0.09) and verbal memory (d = 0.56, P value =
0.06) at one month post-intervention compared to wait-list con-
trols (Milbury 2013). In the short term, immediately post-inter-
vention, the Tibetan SoundMeditation intervention had a benefi-
cial effect on a number of secondary outcomes including: reduced
depressive symptomology (d = 0.59, P value = 0.05); improved
perceived mental health (d = 0.57, P value = 0.04), and improved
spiritual quality of life (d = 0.52, P value = 0.05) compared to wait-
list controls. Despite the moderate effects sizes reported, effects
were not sustained at one month post-intervention. The authors
reported that the primary aim of the study was to gain insight into
the feasibility and initial efficacy of the intervention; and 30% of
breast cancer survivors in their sample experienced objectively as-
sessed cognitive impairment, which may have contributed to the
lack of sustained improvements due to ceiling effects.
Physical activity intervention
Statistically significant improvements (P value < 0.05) in a subtest
of processing speed/executive functions, a subtest of verbal fluency,
a sub scale (impact on QoL) of the FACT-Cog were observed for
participants enrolled in a physical activity intervention compared
to a wait-list control. However, these findings were no longer sig-
nificant when baseline scores were controlled (Campbell 2014).
Adherence to treatment
Where reported, adherence to the interventions was high. Kesler
2013 defined adherence to their intervention as completion of four
sessions per week as well as accuracy in completion of exercises.
Participants completed a mean of four sessions (SD = 0.42) which
took a mean of 13.0 weeks to complete (SD = 0.92, range = 12 to
15) including cognitive assessments. Moreover, accuracy increased
over time as demonstrated by a strong positive association (mean
r = 0.72). Adherence to Tibetan Sound Meditation intervention
had a high level of adherence (M = 9.71, SD = 1.90, range = 7
to 12) (Milbury 2013). All participants completed at least 75%
of the meditation sessions and 23.5% completed all 12 sessions.
Participants were also encouraged to practice at home outside of
the scheduled meditation sessions: 33.4% practiced at home ev-
ery day, 46.5% practiced at home twice a week, 10.1% practiced
at home once a week and 9.5% did not practice at home. The
remaining three studies did not report on adherence to their re-
spective interventions (Campbell 2014; Ferguson 2012; Von Ah
2012).
Treatment satisfaction
There was a high level of participant satisfaction with receipt of
compensatory strategy training (Ferguson 2012; Von Ah 2012),
computer-assisted cognitive training (Von Ah 2012) and Tibetan
Sound Meditation (Milbury 2013). General satisfaction with
Ferguson 2012MAAT interventionwas high (M=7.0, SD=1.05);
a score of zero represents ’not at all satisfied’ and a score of eight rep-
resents ’completely satisfied’. The MAAT intervention was rated
by participants as more helpful in compensating than improving
memory in every day life, with higher scores indicating higher lev-
els of helpfulness (M = 6.7, SD = 1.54 versus M = 5.2, SD = 1.59).
The top five ranked strategies included: applied relaxation, use of a
schedule or daily planner, verbal rehearsal, pacing of activities and
self-instructional training. Von Ah 2012 administered the CSQ
to participants who received the ACTIVE and Insight interven-
tions. Seventy-three per cent of ACTIVE participants and 89% of
Insight participants rated their respective interventions as satisfac-
tory. Participants agreed or strongly agreed that the interventions
were understandable (ACTIVE: 96%; Insight: 89%) and enjoy-
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able (ACTIVE: 81%; Insight: 73%). Eighty per cent and 81%
of participants in the ACTIVE and Insight interventions, respec-
tively, disagreed or strongly disagreed that an alternative interven-
tion was preferable. Moreover, participants disagreed or strongly
disagreed that theywould have preferred the intervention to be de-
livered in an alternative format (ACTIVE: 100%; Insight: 96%).
The majority of participants disagreed or strongly disagreed that
the respective ACTIVE and Insight interventions were too dif-
ficult (77%; 89%), took too much time (92%; 100%) or were
boring (96%; 100%). Seventy-four per cent and 84% of partic-
ipants in Milbury 2013 Tibetan Sound Meditation intervention
rated it as very useful and definitely beneficial, respectively. Par-
ticipants expressed positive experiences also in response to open-
ended questions about the intervention.
D I S C U S S I O N
Summary of main results
Five studies (n = 235) describing six interventions targeting main-
tenance of cognitive functioning or amelioration of cognitive im-
pairment following systemic cancer treatment were included in
this review. Two computer-assisted cognitive training interven-
tions (n = 100) (Kesler 2013; Von Ah 2012), two compensatory
strategy training interventions (n = 95) (Ferguson 2012; Von Ah
2012), one meditation intervention (n = 47) (Milbury 2013) and
one physical activity intervention (n = 19) (Campbell 2014) were
identified. Each study recruited only women who had been treated
for breast cancer and some targeted specific areas of cognition in-
cluding processing speed (Von Ah2012), memory (VonAh 2012),
executive functions (Kesler 2013) and both memory and attention
(Ferguson 2012). Common areas of cognition were assessed across
studies though each area was assessed using a variety of outcome
measures. Thus, wewere only able to undertake limitedmeta-anal-
yses. No beneficial effect of compensatory strategy training was
found for physical well-being immediately or two months post-
intervention or mental well-being two months post-intervention.
Low certainty evidence suggests that compensatory strategy train-
ingmay be associatedwith a reduction inmental well-being imme-
diately post-intervention. If this is a true effect, it may be explained
by the participant’s perceptions of limited benefits as assessed by
objective assessments of cognitive domains other thanmemory for
participants in the intervention group. For example, difficulties in
maintaining attention and executive functions such as planning
and managing multiple tasks are experienced frequently by a sig-
nificant proportion of cancer survivors (Jansen 2005;Wefel 2011).
An improvement on a number of objectively assessed cognitive
outcomes, self-reported cognitive function and mental well-be-
ing was found for computerised cognitive training. Compensatory
strategy training resulted in improvements in objectively assessed
memory, self-reported cognitive function and spiritual quality of
life (QoL). Benefits were observed in terms of participants’ per-
ceptions of their cognitive abilities and quality of life as well as
in terms of the more often found result relating to improvements
in neuropsychological test scores. Given their nature of repetitive
practice of cognitive skills, cognitive training interventions have
the potential for effects to transfer to other cognitive domains.
This was observed in one study (Kesler 2013), but, is unlikely to
occur within compensatory strategy training interventions. The
physical activity and meditation interventions failed to find a ben-
eficial effect on cognitive outcomes compared to a wait-list con-
trol group, although improvements in depressive symptoms, per-
ceived mental health and spiritual QoL were observed for Tibetan
Sound Meditation. Overall, adherence to interventions was good
and interventions were highly rated by participants in terms of
satisfaction.
Overall completeness and applicability of
evidence
The opportunity to pool data or draw robust conclusions about the
effects of tested intervention was limited due to the small number
of studies and the variation across them in terms of interventions
and outcome measures. The incomplete and unclear presentation
of data in papers limited the extent to which we were able to
conduct additionalmeta-analyses.Our requests for additional data
were unsuccessful. The studies were limited to women only who
had been treated for breast cancer and it is uncertain whether the
findings are informative for intervention effectiveness, adherence
or satisfaction for men treated for cancer or women treated for
other types of cancer. Moreover, participants were at least three
months post-chemotherapy and the extent to which interventions
would be effective if delivered earlier, for example, at the end of
treatment is untested. Also, because participants in the studies
tended to be relatively young (53 years old, on average) and to have
a high level of education, it is unclear how cognitive rehabilitation
interventions would impact on cancer survivors with lower levels
of education or on older or younger cancer survivors.
Reports about the interventions and control conditions in the
studies contained only minimal descriptions and posed difficul-
ties with respect to replication. We created a mini-taxonomy of
the main techniques allied to each intervention component in an
attempt to describe and appraise how the interventions ’work’ and
to facilitate between-study comparisons. Many techniques were
used in common across interventions.
None of the studies assessed the cost-effectiveness of their inter-
ventions, and there was limited attention given to safety or adverse
events for participants. Cognitive training programmes were com-
mercially available and there was some access to a programme’s
resources at no cost.
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Quality of the evidence
We considered the quality of evidence for the physical and mental
well-being outcomes of compensatory strategy training. Evidence
was rated low quality due to the risk of bias and imprecision of
estimates. Therefore, results should be interpreted with caution.
In the absence of a GRADE assessment for many outcomes of
interest in the review, readers should consider the methodological
quality of individual studies. None of the studies were rated as hav-
ing a low risk of bias in all domains. Overall, selection bias, perfor-
mance bias and detection bias were well-reported and, in general,
we categorised these as low risk of bias. Although, we assessed the
risk of performance bias as low given the inability of participants
to be blinded to non-pharmacological interventions, we acknowl-
edge that it is possible that participants’ knowledge of allocation
may affect reporting of outcomes. Each study failed to report suffi-
cient information that would permit an adequate judgement of all
’Risk of bias’ items. Attrition bias, reporting bias and baseline im-
balances in cognitive function between groups were infrequently
reported. Although many of the self-report measures of cognitive
functioning were not cancer-specific, the reliability and validity of
their use among cancer populations were less well reported than
objective measures for which no cancer-specific measures which
have been developed. Two studies (Kesler 2013; Von Ah 2012)
had a high risk of bias regarding selective reporting. It appeared
that the measurement properties of the assessments and their ap-
propriateness for use with particular cancer populations and set-
tings was not given due consideration.
Only two studies (Ferguson 2012; Von Ah 2012) reported an a
priori sample size calculation and one study reported a sample size
calculation retrospectively (Milbury 2013). One study (Von Ah
2012) was found to have sufficient power to observe whether or
not the intervention that theywere testinghad an effect. Intention-
to-treat analysis was not undertaken in two studies (Kesler 2013;
Von Ah 2012). Caution is therefore warranted when interpreting
review findings given the limited evidence and individual study
limitations noted above.
Potential biases in the review process
A sensitive search filter rather than a specific filter was developed
to ensure that a wide breadth of interventions was identified due
to the range of different types of non-pharmacological interven-
tions for improving cognitive impairment or maintaining cogni-
tive function. This resulted in the screening of a large number
of reports. The diverse types of interventions made it difficult to
synthesise results and compare studies.
We were interested in interventions that targeted individuals
whose problemswere chronic or long-lasting due to completed sys-
temic cancer therapy. Trials that included individuals who: (i) had
not received systemic treatment and, or (ii) were currently under-
going active treatment were excluded. Nevertheless, it is possible
that individuals at various points on the cancer care trajectory may
also benefit from cognitive rehabilitation-targeted interventions.
Cognitive impairment related to cancer may arise, for example,
due to factors related to becoming a cancer patient such as fatigue,
depression and anxiety. Increasingly, there is evidence that cancer-
related cognitive impairment may be present prior to treatment
commencement and independent of factors such as fatigue, de-
pression and anxiety. Some authors have hypothesised that similar
mechanisms for cancer development and impaired cognitive func-
tion, such as, cytokine production may play a role (Lange 2014).
Agreements and disagreements with other
studies or reviews
Non-pharmacological interventions have been investigated among
other cancer populations or treatment groups who experience
changes in cognition. This research is limited, but findings sug-
gest non-pharmacological interventions may be effective for in-
dividuals with childhood cancers (Castellino 2014), central ner-
vous system (CNS) tumours (Gehring 2008; Gehring 2010), or
who have received cranial radiation (Day 2014). Other reviews
of interventions for cancer- or treatment-related cognitive impair-
ment have reported similar findings to our review (Fardell 2011;
Gehring 2012; Hines 2014; Janelsins 2014; Von Ah 2014). One
recent review (Chan 2015) identified pharmacological and non-
pharmacological interventions for chemotherapy-related cogni-
tive impairment among breast cancer patients and concluded that
non-pharmacological interventions were promising. This differs
slightly from the conclusions drawn from our review whereby we
stated that there is insufficient evidence available. There were some
differences in eligibility criteria, definitions of interventions and
sources between reviews which may have resulted in the minor
differences in conclusion between the reviews particularly as Chan
2015 identifiedmore studies under their umbrella ’cognitive train-
ing’ intervention term encompassing cognitive training and com-
pensatory strategy training which were differentiated within our
review. Nevertheless, both reviews state that further research in
this area is warranted. As our review focused on cognitive impair-
ment related to systemic cancer treatment, we excluded studies
because participants had not received chemotherapy or hormonal
therapy or were in current receipt of chemotherapy. These studies
reported beneficial effects of their interventions as noted below.
Three group cognitive rehabilitation interventions targeting breast
cancer (Ercoli 2015) or diverse cancer sites (Cherrier 2013; King
2015) found improvements in objectively assessed (Ercoli 2015;
King 2015) and subjectively reported cognitive function (Cherrier
2013; Ercoli 2015; King 2015), as well as quality of life (Cherrier
2013) and cognitive self-efficacy (King 2015). A group yoga inter-
vention for individuals from diverse cancer sites (Derry 2015) and
Medical Qigong (Oh 2012) for women with breast cancer found
improvements in self-reported cognitive function.
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Similar to our review, other Cochrane reviews of cognitive reha-
bilitation interventions among other disease groups identified a
small number of studies, of low quality. There was no reported
beneficial effect of intervention on cognition among individuals
with schizophrenia (McGrath 2000), Alzheimer’s disease, vascular
dementia (Bahar-Fuchs 2013) ,or memory (das Nair 2007), exec-
utive function (Chung 2013) and attention deficits as a result of
stroke (Loetscher 2013). Rehabilitation targeting memory did not
have a beneficial effect on outcomes for individuals with multiple
sclerosis (das Nair 2012). Promising effects of cognitive rehabili-
tation on divided attention have been reported among individuals
with stroke (Loetscher 2013), memory among healthy individuals
and individuals with mild cognitive impairment (Martin 2011).
Cognitive training on memory and cognitive training combined
with neuropsychological rehabilitation has also had beneficial ef-
fects on immediate-, delayed-verbalmemory and attention among
individuals with multiple sclerosis (Rosti-Otajärvi 2014). It may
be difficult to make like-with-like comparisons about the effec-
tiveness of interventions across disease groups given the different
aetiological pathways and potential for cognitive functioning to
be re-mediated or restored after diagnosis and/or treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The limited evidence available at present makes it difficult to draw
firm recommendations for healthcare providers that would help
patients maintain or recover cognitive functions following receipt
of chemotherapy. Further research is needed to resolve uncertain-
ties about the effects of available interventions. Tentatively, the
review findings suggest that cognitive- and compensatory strat-
egy-training may have potential benefits for improving cognitive
functioning and quality of life outcomes among breast cancer sur-
vivors. Also, evidence on the effectiveness of physical activity and
meditation interventions on cognitive function outcomes is too
weak to extract any implications for clinical practice. Although,
not an objective of the review, it is not clear if face-to-face or group-
delivered interventions would have most benefit or which type of
healthcare professional would be best placed to deliver such inter-
ventions.
Implications for research
We identified only a small number of trials and these were not
of high quality. Nevertheless, the number of ongoing, registered
trials, suggest that more rigorous research in this area might be
available in future. Larger, multi-site trials are needed with longer
follow-up periods in order to test robustly the effectiveness of
interventions. Moreover, trials that are adequately powered with
a formal sample size calculation conducted a priori are needed.
Future studies should consider methods to blind participants to
group allocation such as the use of attentional control groups. It
is recognised that due to the cognitive rehabilitation nature of the
interventions identifying an appropriate attentional control may
be difficult. It is important to consider the extent to which practice
effects may occur as a result of multiple neuropsychological test-
ing and how this factor may lead to improvements in test scores
which may be independent of any true intervention effects. For
example, if patients remember the content and responses of neu-
ropsychological tests, develop strategies or have increased confi-
dence to complete the tests, this may contribute to practice ef-
fects. Future studies should continue to consider use of alternative
test battery forms, test measures with good test-retest reliability to
capture with more precision true changes in cognition which may
help to control or lessen the impact of practice effects (Calamia
2012; Vardy 2008; Wefel 2011).
Many of the included studies required participants to self-report
deterioration in cognitive functioning since cancer diagnosis and
cancer treatment. It is widely known that self-reported cognitive
functioning demonstrates a stronger association with fatigue, dis-
tress and related factors than objective measures of cognitive func-
tioning (Green 2005). Whilst some of the studies assessed retro-
spectively the proportion of study participants who demonstrated
objectively assessed cognitive impairment, there is a need also to
do so prior to study enrolment in future trials. As with most can-
cer survivorship research and, indeed, research on treatment-re-
lated cognitive impairment among non-CNS adult-onset cancers,
breast cancer represents the most widely studied cancer survivor
cohort. However, cognitive impairment following systemic cancer
treatment is a phenomenon relevant to survivors of other cancers
and they too should be considered in future trials.
Further work is needed to determine the psychometric proper-
ties of measures of cognitive functioning within cancer patient or
survivor populations to ensure that they are appropriate for use,
as cognitive impairments among this group occur more subtly
than the groups for which the measures were initially designed.
There was little agreement across trials about the choice of out-
come measures for specific cognitive domains and often, measures
were used to assess more than one cognitive domain. The Interna-
tional Cognition and Cancer Task Force published recommenda-
tions for outcome measure selection (Wefel 2011) and adherence
to these would permit ease of comparison and meta-analysis in
future reviews. Measuring activities of daily living (ADLs) and in-
strumental ADLs are important outcomes to be captured in future
trials.
Future research should consider also incorporating neuroimaging
techniques into their evaluation design to demonstrate structural
and functional changes in the brain as an additional objective as-
sessment of changes in cognitive functioning. Although research
in this area is in its infancy, in the future it may be beneficial
to test the effectiveness of interventions targeting maintenance of
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cognitive function or amelioration of cognitive impairment in a
preventative setting, particularly among cancer patients who may
have increased susceptibility to the neurotoxic effects of chemo-
therapy (e.g. presence of apoE ǫ4 allele). At present, there is no
standard care for treatment-related cognitive impairment and the
cost-effectiveness of implementing cognitive rehabilitation inter-
ventions in clinical practice is warranted in future studies, given
limited healthcare resources.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Campbell 2014
Methods Randomised controlled trial
Intention-to-treat analysis: ITT was undertaken as no participants were missing post-
intervention
Loss to follow-up: numbers and reasons (partially) reported in flowchart
Participants Inclusion Criteria
Females, postmenopausal, aged 40-65 years old diagnosedwith stages I-IIIA breast cancer
who have received chemotherapy at least three-months previously and had completed
all treatment within the last three years, currently using hormonal therapies who were
reporting cognitive changes since chemotherapy receipt and who were undertaking less
than90minutes of physical activity perweek in the last 6months andwhowere physically
able to undertake moderate to vigorous physical activity
Exclusion Criteria
Self-report of greater than 90 minutes per week of moderate physical activity within the
last 6 months, or a MMSE score less than 23 or a co-morbid condition which may alter
cognitive testing results (i.e. a clinically diagnosed major depression, anxiety disorder, or
other psychiatric condition, meeting DSM IV criteria) or history of substance abuse or
other neurological disorder (i.e. head injury, epilepsy, tumour, neurodegenerative disease)
or ruled ineligible for fMRI scanning (i.e. metal implants)
Randomisation method: Sequentially numbered opaque envelopes, based on a ran-
domisation schedule prepared by a research. assistant not involved with the study using
varying blocks of 4 to 6
No. of participants: 19 (I: 10; C: 9)
Cancer site(s): Breast stages I-IIIA
Age: I: mean=53.2 (SD = 5.1); C: 51.4 (SD = 7.0)
Sex: Female
Treatment history: All patients received chemotherapy and had completed treatment
within the last three years. All participants were currently receiving hormonal treatments
Co-morbidities: None reported.
Education: Some college are or less (I: 3 (30%)/ C: 3 (33%)); College graduate (I: 4
(40%)/ C: 5 (56%)); Post-college graduate or above (I: 3 (30%); C: 1 (11%))
Socio-economic status: None reported.
Cognitive impairment at baseline: Participants had to self-report persistent cognitive
changes following chemotherapy
Country: Canada
Interventions Definition: Aerobic exercise intervention
To assess the effectiveness of the intervention on cancer-related cognitive function and
QoL
Duration: 24 weeks, progressively increased with expectation to rest full exercise pre-
scription by week 8. Participants were required to attend two 45-minute supervised ses-
sions and two independent 30-minute sessions at home, per week
Components: Aerobic exercise (150 minutes/week of aerobic exercise at 60% to 70% of
heart rate reserve- individualised based on baseline VO2 peak test), including supervised
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Campbell 2014 (Continued)
sessions and home sessions
Techniques
Goal setting: all participants to reach full exercise prescription by week 8
Graded tasks: all participants to reach full exercise prescription by week 8
Generalisation of a target behaviour: to transfer exercise from supervised sessions to home
Instruction on how to perform behaviour: supervised sessions
Demonstration of the behaviour: supervised sessions
Materials: None reported
Setting: Supervised setting (no details of where) and independent, home-based sessions
Therapist/training: Not reported
Theoretical basis/mechanism: None reported
Comparison group:Delayed exercise group
Outcomes Assessed at baseline and post-intervention
Subjective cognitive functioning: *FACT-Cog (version 3) 4 domains: Perceived cog-
nitive impairments; Impact on QoL; Comments of others; Perceived cognitive abilities
Objective cognitive functioning: **Stroop test to assess attention and processing speed;
Hopkin’s Verbal Learning Test (total recall; delayed recall; retention and; delayed recog-
nition index) to assess memory and learning; COWAT “F” “A” “S” word and animal
naming to assess verbal fluency; Trail Making Test (trials A, trials B and trials difference)
to assess processing speed and executive functioning
Adherence: None reported
Safety issues: None reported
Adverse effects: None reported
Notes *Appears to be the primary outcome in the Conference poster.
**Stated as primary outcome on protocol on trial register.
I = 9/C = 7 of the participants underwent fMRI tests whilst being administered the
Stroop Task at baseline and post-intervention
Objectivemeasures were selected based on recommendations by the International Cancer
and Cognition Task Force
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Individuals were randomized using se-
quentially numbered opaque envelopes, us-
ing varying blocks of 4-6” (Author corre-
spondence)
Allocation concealment (selection bias) Low risk “Prepared by a research assistant not in-
volved with the study” (Author correspon-
dence)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants to a physical
activity intervention
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Campbell 2014 (Continued)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Neuropsychological test measurements
were undertaken by a trained tester. Infor-
mation about trial on clinicaltrials.gov in-
dicates that outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for throughout
study, however, not all participants com-
pleted fMRI assessment at end of the study
and reasons for non-completion were not
accounted for.Nevertheless the results from
the fMRI are not reported in this review
Selective reporting (reporting bias) Low risk All outcomes are reported.
Baseline imbalances in cognition scores
Objective outcomes
Unclear risk None reported.
Baseline imbalances in cognition scores
Subjective outcomes
Unclear risk None reported.
Validity of cognitive function measures
Objective outcomes
Low risk Based on International Cognition and
Cancer Task Force recommendation, mea-
sures with good psychometric properties
for non-CNS cancers
Validity of cognitive function measures
Subjective outcomes
Unclear risk None reported.
Reliability of cognitive function measures
Objective outcomes
Low risk Based on International Cognition and
Cancer Task Force recommendation- mea-
sures with good psychometric properties
for non-CNS cancers
Reliability of cognitive function measures
Subjective outcomes
Unclear risk None reported.
Ferguson 2012
Methods Randomised controlled trial
Intention-to-treat analysis: ITT was undertaken using linear interpolation methods
used to infer missing data to maintain power for the analysis
Lost to follow-up: numbers reported in flowchart and reasons reported in text
Participants Inclusion criteria
Females at least 18 years of age diagnosed with stages I-II breast cancer, at least 18months
post-treatment and currently disease-free with previous chemotherapy receipt with self-
reported problems with memory or attention following chemotherapy and who were
able to speak and read English
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Exclusion criteria
Current psychiatric disorder, neuro-behavioural risk factors, history of CNS disease or
receipt of treatment for CNS cancer
Participants were recruited via newspaper advertisements, letters to cancer survivors from
the Comprehensive Breast Program at Dartmoth-Hitchcock Medical Center and fliers
to other medical oncology offices
Randomisation method: computer-generated assignment
No. of participants: 40 (I: 19/ C: 21)
Cancer site(s): Stages I-II breast cancer
Age: I: mean = 51.21 (SD = 7.3); C: mean = 49.43 (SD = 5.1)
Sex: Female
Treatment history: All patients received chemotherapy and were at least 18 months
post-chemotherapy. Use of hormonal therapies (I: 11/C: 12)
Co-morbidities: None reported
Education: Completed some years of college or less (I: 3 (30%)/ C: 3 (33%)); College
graduate (I: 4 (40%)/ C: 5 (56%)); Post-college graduate or above (I: 3 (30%); C: 1
(11%))
Socio-economic status: None reported
Cognitive impairment at baseline: Participants had to self-report persistent memory
or attention problems following chemotherapy
Country: USA
Interventions Definition: Brief CBT Memory and Attention Adaptation Training (MAAT).
To assess the efficacy of MAAT on self-reported and objective cognitive dysfunction
related to cancer, as well as QoL
Duration: Twice-weekly 30- to 50-minute sessions for 8 weeks delivered face-to-face
with telephone follow-up in between clinics. Participants were encouraged to apply the
strategies to daily situations
Components: Four CBT components incorporated into MAAT: Education; Self-aware-
ness training; Self-regulation training and; Cognitive compensatory strategy training.
MAAT workbook given to each participant
Techniques
Feedback on behaviour: telephone contact to reinforce use or modification of strategies
Self-monitoring of behaviour: participants to record ’at-risk’ situations which contribute
to cognitive impairment Instruction on how to perform behaviour: learn compensatory
strategies, workbook Information about antecedents of behaviour: education about find-
ings and current knowledge regarding cancer-related cognitive impairment and partici-
pants to identify ’at-risk’ situations which lead to cognitive difficulties
Information about the health consequences: education about findings and current knowl-
edge regarding cancer-related cognitive impairment
Demonstration of the behaviour: taught compensatory strategies
Prompts/cues: telephone contact, external cueing
Behavioural practice/rehearsal: rehearse compensatory strategies
Generalisation of a target behaviour: application of strategies to everyday life
Reduce negative emotions: applied relaxation (Self-regulation training) and stress-man-
agement
Mental rehearsal of successful performance: visualisation strategies
Self-talk: verbal rehearsal, covert verbal self-instruction (self-instructional training)
Materials: Clinician’s manual, participant booklet
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Theoretical basis/mechanism: CBT/Compensatory strategy training
Setting: Face-to-face, Dartmouth Medical Centre
Therapist/Training: Clinical Psychologist
Comparison:Wait-list control
Outcomes Outcomes were assessed at baseline, post-intervention and two-months intervention
with the exception of depression, anxiety and treatment satisfaction
Subjective cognitive function: *MASQ 5 domains (language; visuo-perceptual; verbal
memory; visual memory; attention)
Objective cognitive function: CVLT (total raw scores across trials 1-5) to assess verbal
memory; D-KEFS (trail-making letter trial; colour-word interference; colour-word and
switching trials) and WAIS-III (digit symbol-coding subset) to assess processing speed
Other outcomes: QOL-CS 41-item scale, 5 domains (physical; psychological; social
and; spiritual) to assess quality of life; CES-D to measure depression; STAI to measure
anxiety; Treatment satisfaction measured by a study-specific measure
Adherence: None reported
Safety issues: None reported
Adverse effects: None reported
Notes *Primary outcome in Ferguson study.
Alternate forms of the CVLT were used to counteract practice effects
Linear interpolation methods used to account for 5 dropouts over the course of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants...randomized to treatment
and waitlist conditions using computer
generated assignment.” Pg 178
Allocation concealment (selection bias) Low risk None reported, however, due to the com-
puterised nature of the allocation it is un-
likely that study personnel or participants
can predict which allocation is next, how-
ever, it may be manipulated by re-running
the software for a given participant
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind the participants to
group allocation. “It was impossible to
blind the clinician to the treatment or con-
trol assignments.” Pg 179
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk “The research assistant completing all as-
sessment and testing was blind to partici-
pant group membership.” Pg 178
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for dropout reported and number
of dropouts across groups was similar. Pg
180 Intention-to-treat analysis was imple-
mented and linear interpolation methods
were used to impute missing values
Selective reporting (reporting bias) Unclear risk Anxiety and depression may not have been
outcome measures but were measured to
gauge any changes in mood over the course
of the study period.However, no numerical
data or detailed data included
Baseline imbalances in cognition scores
Objective outcomes
Unclear risk No baseline differences between groups are
reported.
Baseline imbalances in cognition scores
Subjective outcomes
Low risk Trend for increased cognitive impairment
in intervention group compared to control
group, but this is not significant. Pg 182
Validity of cognitive function measures
Objective outcomes
Unclear risk Measures chosen for ability to discriminate
between survivors who have or have not
received chemotherapy. Pg 179
Validity of cognitive function measures
Subjective outcomes
Unclear risk No information reported on the validity of
outcome.
Reliability of cognitive function measures
Objective outcomes
Unclear risk No information reported related to relia-
bility of outcome measures
Reliability of cognitive function measures
Subjective outcomes
Unclear risk No information reported related to relia-
bility of outcome measure
Kesler 2013
Methods Randomised controlled trial
Intention-to-treat: ITT was not undertaken
Loss to follow-up: numbers and reasons reported in text
Participants Inclusion criteria
Females at least 40 years of age diagnosed with stages I-IIIA breast cancer with a history
of breast cancer treatment including surgery and chemotherapy at least 18 months post-
chemotherapy receipt with home Internet connection. Participants were not excluded if
they had received radiotherapy or hormonal therapy
Exclusion criteria
Chemotherapy receipt prior to cancer treatment or colour blindness or major sensory
deficit or neurological or major medical condition which may affect cognitive function
or history of inpatient, psychiatric hospitalisation or current psycho-stimulant or CNS
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depressant medication use (with the exception of use of common antidepressants)
Participants were recruited from advertisements and physician referral.
Randomisation method: randomised by computerised coin toss software
Participants: 41 (I: 21/ C: 20)
Cancer site(s): Breast cancer stages I (I: 25/ C: 26); II (I: 50/ C: 42); III (I: 25/ C: 32)
Age: I: mean = 55 +/- 7; C: mean = 56 +/- 6
Sex: Female
Treatment history: All patients received chemotherapy and were at least 18 months
post-chemotherapy. Receipt of radiotherapy (I: 70%/ C: 63%) and; use of hormonal
therapies (I: 60%/C: 63%)
Co-morbidities: None reported
Education: I: 16 years +/- 2/ C: 16 years +/- 3
Socio-economic status: None reported
Cognitive impairment at baseline: Participants did not have to report cognitive im-
pairment to be eligible for the study
Country: USA
Interventions Definition: Computer-based cognitive training program for executive functioning (pro-
vided by Lumos labs (Lumiosity))
To assess the feasibility and effectiveness of a home-, computer-based, cognitive training
program on executive functioning
Components: Thirteen cognitive training exercises targeting cognitive flexibility, work-
ing memory, processing speed and verbal fluency. Adaptive program which increased in
difficulty. Initially low difficulty with cues and explanations; change in difficulty based
on algorithms considering inter- and intra- session performance including speed and
accuracy. Immediate visual and auditory feedback and reinforcement regarding perfor-
mance
Techniques
Feedback on behaviour: Immediate visual and auditory feedback
Feedback on outcome(s) of behaviour: Immediate visual and auditory feedback
Instruction on how to perform the behaviour: written or animated instructions before
each task
Demonstration of the behaviour: written or animated instructions before each task
Prompts/cues: Weekly telephone calls to enhance compliance to programme
Behavioural practice/rehearsal: completion of computer exercises
Graded tasks: Adaptive ability
Materials: Written instructions, computer, online computer programme
Duration: 48 sessions over a 12-week period (4 sessions a week) lasting 20-30 minutes
Theoretical basis/mechanism: None reported
Setting: Home
Personnel: Clinical Neuropsychologist at initial assessment
Comparison:Wait-list control
Outcomes Outcomes were assessed at baseline and post-intervention
Subjective cognitive function: Behavioral Rating Inventory of Executive Functioning
(BRIEF) 3 scores (global executive functioning composite score; task monitoring and;
plan and’/or organise to assess self-reported executive functioning
Objective cognitive function: *WCST to assess cognitive flexibility; D-KEFS letter
fluency test to assess executive functioning and language; HVLT-R to assess verbal mem-
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ory; WAIS (digit span) to assess working memory and; WAIS (symbol search) to assess
processing speed
Secondary outcomes: CAD to assess depression, anxiety and cognitive fatigue.
Adherence: Time and date of each exercise, session performance and duration of each
exercise and session were recorded. Adherence was seen as 4 sessions per week with a
linear positive trend in performance
Safety issues: None reported
Adverse effects: None reported
Notes *Primary outcome in paper.
Alternate forms of DKEFS and HVLT were used to counteract practice effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...randomized by computer coin toss soft-
ware” Pg 301
Allocation concealment (selection bias) Low risk None reported, however, due to the com-
puterised nature of the allocation it is un-
likely that study personnel or participants
can predict which allocation is next
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants to a cognitive
training intervention
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk “Testing was administered by trained re-
search staff members who were blinded to
the intervention assignment and time point
of the participants” Pg 303
Incomplete outcome data (attrition bias)
All outcomes
High risk All participants accounted for with reasons
given.Dropouts were similar across groups.
Pg. 303 Table 2 which presents the key re-
sults section results does not highlight the
differences in numbers pre- and post-in-
tervention. Missing data were not imputed
and intention-to-treat analysis was not un-
dertaken
Selective reporting (reporting bias) Low risk All outcomes were reported in the paper.
Baseline imbalances in cognition scores
Objective outcomes
Unclear risk None reported.
Baseline imbalances in cognition scores
Subjective outcomes
Unclear risk None reported.
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Validity of cognitive function measures
Objective outcomes
Low risk “The WCST...discriminates between BC
survivors who were treated with chemo-
therapy and non cancer controls”
“The HVLT-R and verbal fluency tests
have previously been shown to discriminate
between BC patients and survivors, and are
among the tests recommendedby the Inter-
national Cognition andCancer Task Force.
..”
’Digit span also has been shown to discrim-
inate between BC survivors and controls’
Pg 303
Validity of cognitive function measures
Subjective outcomes
Low risk “The BRIEF not only discriminates be-
tween BC and controls but also correlates
significantly with deficits in prefrontal cor-
tex among BC survivors” Pg 303
Reliability of cognitive function measures
Objective outcomes
Low risk “TheWCSThas been shown to be robustly
sensitive to abnormalities in executive-pre-
frontal neurocircuitry...and discriminates
between BC survivors who were treated
with chemotherapy and non cancer con-
trols” Pg 303
Reliability of cognitive function measures
Subjective outcomes
Unclear risk No information reported.
Milbury 2013
Methods Randomised controlled trial
Intention-to-treat analysis: ITT was undertaken
Loss to follow-up: numbers reported in flowchart and reasons reported in text
Participants Inclusion criteria
Females aged 18 years and over diagnosed with stages I-IIIA breast cancer, proficient in
English who had received chemotherapy 6 to 60 months previously, were currently using
hormonal therapies, reporting cognitive impairment post-treatment and lived within 2
hours driving distance of institution
Exclusion criteria
Documented diagnosis of thought disorder (e.g. schizophrenia) or neurological injury
or a MMSE of less than or equal to 23 or metastatic/recurrent cancer or prior regular
meditation practice
Participants were identified from institution’s electronic medical records and posted
invitations to the study
Randomisation method:minimisation, an adaptive randomisation method evenly bal-
anced according to age, time since diagnosis, menopausal status, receptor status, of dis-
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ease, surgical procedure, type of hormone treatment stage other medications with pos-
sible cognitive effects, and baseline self-report cognitive function scores
Participants: 47 (I: 23/ C: 24)
Cancer site(s): Breast cancer stages I (I: 6/ C: 6); II (I: 13/ C: 13); III (I: 4/ C: 5)
Age: I: mean = 53.0 (SD = 6.6); C: mean = 54.1 (SD = 8.6)
Sex: Female
Treatment history:All patients received chemotherapy andwere between6 to 60months
post-chemotherapy and current use of hormonal therapy. Receipt of radiotherapy (I: 17/
C: 19) and; surgery (I: 20/C: 24)
Co-morbidities: None reported
Education: Some college or higher (I: 22/ C: 18)
Socio-economic status: None reported
Cognitive impairment at baseline: Participants had to have cognitive impairment re-
lating to chemotherapy assessed by 4 items of the FACT-Cog
Country: USA
Interventions Definition: Tibetan Sound Meditation (TSM) delivered by trained meditation instruc-
tors
To assess the feasibility and efficacy of TSM to improve cognitive functioning and QoL
Duration: Twice weekly (one-hour) sessions over a 6-week period
Components: Breathing, awareness and concentration techniques. Visualisation and
sound exercises with three, separate but inter-related stages and associated cognitive
activity including: stage one acknowledging, cleansing and releasing negative thoughts;
stage two identifying and retrieving a positive supportive quality and; stage 3 integrating
quality into everyday life
Techniques
Social support (unspecified): group setting for delivery of intervention
Instruction on how to perform the behaviour: supervision, CD and written instructions
Demonstration of the behaviour: supervision, CD and written instructions
Behavioural practice/rehearsal: attendance at session and home practice
Generalisation of target behaviour: transference of practice from supervised sessions to
home
Reduce negative emotions: meditation ’releasing negative thoughts’, breathing
Framing/reframing: identifying a positive, supportive quality
Materials: CD, printed instructions
Theoretical basis/mechanism: Mind-body practice may target cognitive impairment
via stress reduction and regulation of immune system
Setting: Instructor-led sessions at institution, participants also encouraged to practice at
home
Personnel:Meditation instructors
Comparison:Wait-list control
Outcomes Self-report outcomes were assessed at baseline, post-intervention and one-month post-
intervention
Objective cognitive function outcomes were assessed at baseline and one-month post-
intervention in order to counteract practice effects
Subjective cognitive function: *FACT-Cog (version 3) 4 domains: Perceived cognitive
impairments; Impact on QoL; Comments of others; Perceived cognitive abilities
Objective cognitive function: *Digit Symbol Test to assess visuo-motor co-ordination,
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processing speed and attention; *Digit SpanTest to assessworkingmemory and attention;
*RAVLT to assess verbal memory and; *COWAT to assess verbal fluency
Secondary outcomes: SF-36 (physical andmental component summary scores) to assess
health-relatedQoL; FACT-spiritual to assess spiritual QoL; CES-D to assess depression;
BFI to assess fatigue; PSQI to assess sleep disturbances; weekly, brief evaluation of classes
to assess satisfaction with intervention
Adherence: Class attendance and frequency of home practice
Safety issues: None reported
Adverse effects: None reported
Notes *Primary outcome measures in study.
Participants were rewarded with a small gift to the value of $25 for completing each
assessment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...participants were randomly assigned to
either the TSMorWLC group by a form of
adaptive randomization called minimiza-
tion [63] so that the groups were evenly
balanced according to age, time since di-
agnosis, menopausal status, receptor status,
stage of disease, surgical procedure, type of
hormone treatment (e.g. tamoxifen vs. AIs)
, other medications with possible cognitive
effects (e.g. Effexor), and baseline subjec-
tive reports of cognitive function (FACT-
Cog total score).” Pg 2356
Allocation concealment (selection bias) Unclear risk No further information reported about
randomisation procedure: likely that with
the use of minimisation in a small, single-
centred study, allocation could be predicted
if previous allocation is known
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants to a TSM in-
tervention.
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One person who dropped out from con-
trol prior to Time point 3 assessment was
unaccounted for. All other drop-outs were
accounted for.” Pg 2358 Intention-to-treat
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analysis undertaken, no description of how
missing values were imputed
Selective reporting (reporting bias) Unclear risk Raw means, SDs and effect sizes only were
reported for all outcomes in tables 2 and
3. No P values or confidence interval re-
ported, we relied on author’s reporting of
significant group differences in text in rela-
tion to intervention effectiveness
Baseline imbalances in cognition scores
Objective outcomes
Unclear risk “There were also no significant differences
in patient characteristics (except for ethnic-
ity) or any of the objective and subjective
outcome variables (see Table 1).” pg 2357.
However, cognition scores are not reported
in Table 1 and no P values or confidence
intervals are reported in the Tables 2 and
3 where information relating to these out-
comes are found
Baseline imbalances in cognition scores
Subjective outcomes
Unclear risk “There were also no significant differences
in patient characteristics (except for ethnic-
ity) or any of the objective and subjective
outcome variables (see Table 1).” pg 2357
However, cognition scores are not reported
in Table 1 and no P values or confidence
intervals are reported in the Tables 2 and
3 where information relating to these out-
comes are found
Validity of cognitive function measures
Objective outcomes
Unclear risk None reported.
Validity of cognitive function measures
Subjective outcomes
Unclear risk None reported.
Reliability of cognitive function measures
Objective outcomes
Unclear risk None reported.
Reliability of cognitive function measures
Subjective outcomes
Unclear risk None reported.
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Methods Randomised controlled trial
Intention-to-treat analysis: ITT was not undertaken
Loss to follow-up: numbers and reasons reported in flowchart
Participants Inclusion criteria
Females aged 40 years and over diagnosed with breast cancer, currently disease-free, post-
menopausal, able to read, write and understand English who at least one-year post-treat-
ment with a history of chemotherapy receipt for non-metastatic breast cancer, reporting
cognitive impairment post-treatment which negatively impacted their daily lives
Exclusion criteria
Substantial cognitive impairment (MMSE < 24), history of cranial radiation or intrathe-
cal therapy, stroke, encephalitis, traumatic brain injury, brain surgery, Alzheimer’s disease
or Parkinson’s disease, current active major depression, substance abuse, history of bipo-
lar disorder, psychosis, schizophrenia or learning disability, history of, or current other
cancer (with the exception of basal cell skin cancer) or uncorrected vision problems
Participants were sequentially recruited from Midwestern Cancer Centre and affiliated
clinics and advertisements were posted to research registry participants
Participants: 88 (I1: 29/ I2: 30/ C: 29)
Cancer site(s): Breast 89% of total sample were stage II and under.
Age: I1: mean = 55.19 (SD = 7.58); I2: 56.93 (SD = 7.83); C: mean = 57.21 (SD = 9.
80)
Sex: Female
Treatment history: All participants received chemotherapy and surgery and 74% of
participants also received radiotherapy
Co-morbidities: None reported
Education: I1: mean = 15.96 years (SD = 1.87); I2: mean = 15.63 years (SD = 2.50);
C: mean = 15.43 (SD=2.27)
Socio-economic status: None reported
Cognitive impairment at baseline: Participants had to report cognitive impairment
and its impact on daily life
Country: USA
Interventions Intervention one
Definition: Memory Training (adapted from the Advanced Cognitive Training for In-
dependent and Vital Elderly)
To assess the acceptability/satisfaction and efficacy of memory training on improving
cognitive function
Components: Sessions 1-5: Instruction and strategies to practice techniques for remem-
bering (including multiple mnemonic techniques). Sessions 6-10 provided additional
practice exercises to promote self-efficacy with regards to performance
Techniques:
Social support (unspecified): group setting for delivery of intervention
Instruction on how to perform the behaviour: teaching and instruction of compensatory
strategies
Demonstration of the behaviour: teaching and instruction of compensatory strategies
Behavioural practice/rehearsal: strategy practice exercises
Materials: none reported
Theoretical basis/mechanism: none reported
Duration: 10 one-hour sessions over a 6-8 week period
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Setting: Group-based setting with 3-5 participants in each
Personnel: Trained interventionists
Comparison: Wait-list control
Intervention two
Definition: Speed of processing training (commercially available computer-based ’In-
sight’ program from Posit Science)
To assess the acceptability/satisfaction and efficacy of speed of processing training on
improving cognitive function
Components: Progressively difficult information-processing tasks whereby stimulus du-
ration is systematically reduced
Techniques
Feedback on behaviour: programme gives feedback in terms of performance
Feedback on outcome(s) of behaviour: programme gives feedback in terms of perfor-
mance
Social support (unspecified): intervention delivered in group setting
Behavioural practice/rehearsal: practice exercises
Graded tasks: increasingly difficult exercises
Materials: None reported
Theoretical basis/mechanism: None reported
Duration: 10 one-hour sessions over a 6- to 8-week period
Setting: Group-based setting with 3 to 5 participants in each
Personnel: Trained interventionists
Comparison:Wait-list control
Outcomes Outcomes assessed at baseline, post-intervention and 2-month post-intervention
Subjective cognitive function: FACT-Cog (version 2) and Squire Subjective Memory
Questionnaire
Objective cognitive function: *Composite score of RAVLT (sum recall (trials 1-5), short
delay, recognition score) and *Rivermead Behavioural Paragraph Recall Test (RBPRT)
(immediate recall) to measure immediate memory recall; composite score of RAVLT
(long-term delay score) and RBPRT (long-term delay score) to assess delayed recall;
composite score of Useful Field of View (3 subtests) to measure speed of processing
Secondary outcomes: SF-36 (physical and mental component summary scores), QOL-
CS and QLI-C to assess QoL; FACT-F to assess fatigue; CES-D to assess depression;
STAI to assess anxiety; acceptability using a study-specific scale and Client Satisfaction
Questionnaire to measure satisfaction with intervention
Adherence: Completion rates
Safety issues: None reported.
Adverse effects: None reported.
Notes *Primary outcomes measured in study.
Participants received $25 for each data collection visit.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomized using non-
stratified blocks of 9.” Pg 800
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Allocation concealment (selection bias) Low risk “Biostatisticians provided a password pro-
tected randomization list to the non-
blinded project manager who had primary
responsibility for randomization. Partici-
pants were notified by telephone of group
assignment and interventiondates.” Pg800
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Participants were notified of group allo-
cation and intervention dates”’ Pg 800 It
is not possible to blind participants from
group allocation
“...single-blind study..” Pg 800
“Each intervention...delivered by separate
trained and certified interventionists to
avoid diffusion of treatments.” Pg 800
“...non-blinded project manager who had
responsibility for randomization.” Pg 800
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk “...neuropsychological testing and ques-
tionnaires collected by a trained and
blinded staff member.” Pg. 800
Incomplete outcome data (attrition bias)
All outcomes
High risk All participants accounted for and reasons
reported. Pg 803Missing data were not im-
puted and intention-to-treat analysis was
not undertaken
Selective reporting (reporting bias) Unclear risk Authors created composite objective cog-
nition scores from a number of individ-
ual measures; means and SDs on individ-
ual measures and composite scores are not
reported at both follow-ups, although, re-
liable improvement and net effect sizes are
reported
Baseline imbalances in cognition scores
Objective outcomes
Low risk “There were no significant group differ-
ences at baseline in...cognitive abilities (im-
mediate and delayed memory and process-
ing speed).” Pg 802
Baseline imbalances in cognition scores
Subjective outcomes
Unclear risk No mention of subjective cognitive out-
comes when describing baseline group dif-
ferences
Validity of cognitive function measures
Objective outcomes
Unclear risk None reported.
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Validity of cognitive function measures
Subjective outcomes
Unclear risk None reported.
Reliability of cognitive function measures
Objective outcomes
Unclear risk None reported.
Reliability of cognitive function measures
Subjective outcomes
Unclear risk None reported.
Abbreviations: BC = Breast cancer; BRIEF = Behavioral Rating Inventory of Executive Functioning;BFI = Brief Fatigue Inventory;
CAD = Clinical Assessment of Depression; CBT = Cognitive behavioural therapy; CD = Compact Disc; CNS = Central Nervous
System; CES-D = Centre for Epidemiological Studies- Depression scale;C = control; COWAT = Controlled Oral Word Association
Test; CVLT = California Verbal Learning Test-II; D-KEFS = Delis-Kaplan Executive Function System; DSM IV = Diagnostic
Statistical Manual (version IV); FACT-Cog = Functional Assessment of Cancer Therapy- Cognition subscale; FACT-F = Functional
Assessment of Cancer Therapy-Fatigue subscale; FACT-Spiritual = Functional Assessment of Cancer Therapy-Spiritual subscale;
fMRI = functional Magnetic Resonance Imaging; HVLT-R= Hopkin’s Verbal Learning Test- Revised; ITT = Intention-to-treat; I =
intervention; MMSE = Mini-Mental Status Examination; MASQ = Multiple Ability Self-report Questionnaire; PQSI = Pittsburgh
Sleep Quality Index; QLI-C = Quality of life index- cancer version;QoL = Quality of Life; QOL-CS = Quality of life- Cancer
Survivor; RAVLT = Rey Auditory Verbal Learning Trial; SD = Standard Deviation; SF-36 = Short Form Health Survey- 36 item;
STAI = State Trait Anxiety Index; VO2 = Volume oxygen; WLC = wait-list control; WAIS-III = Wechsler Adult Intelligence-III;
WCST = Wisconsin Card Sorting Test
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez 2013 Not a randomised controlled trial: participants acted as own wait-list controls
Antony 2013 Unable to establish contact with author
Beatty 2010 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Beebe 2014 Could not be contacted
Bernstein 2012 Data not yet available
Boesen 2005 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Boesen 2011 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Bollman 2008 Unable to establish contact with author
Cherrier 2013 Proportion of participants have not received systemic treatment
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Cherrier 2015 Not enough information available to decide if trial should be included
Cimprich 1993 Participants unlikely to have received systemic treatment as first assessment was 3 days following surgery
Cimprich 2003 Participants unlikely to have received systemic treatment as first assessment was prior to surgery
Culos-Reed 2006 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Derry 2015 Proportion of participants have not received systemic treatment
Dolbeault 2009 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Doorenbos 2006 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Duong 1997 Unable to establish contact
Ercoli 2013 Not a randomised controlled trial: pre-post design
Ercoli 2015 Proportion of participants have not received systemic treatment
Ferguson 2007 Not a randomised controlled trial: single-arm pilot study
Ferguson 2014 No data available yet
Freeman 2015 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Galiano-Castillo 2013 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Goedendorp 2014 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Gopinath 2011 Unable to establish contact with author
Hartmann 2007 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Hartmann 2014 Proportion of participants have not received systemic treatment
Haynes 2013 No response from study authors
Hunter 2014 Not a randomised controlled trial: correspondence
Janelsins 2012b No response from study authors
Johns 2015 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Johnston 2011 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
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Kervick 2005 Unable to establish contact with author
Kim 2008 Proportion of patients currently receiving chemotherapy
King 2015 Proportion of participants have not received systemic treatment
Kolidas 2012 No response from study authors
Korstjens 2006 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Korstjens 2011 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Larkey 2015 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Lee 2012a Protocol only available at present
Lee 2012b Protocol only available at present
Lengacher 2012 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Lengacher 2015 Not a randomised trial
Lesiuk 2015 Proportion of patients currently receiving chemotherapy
Luctkar-Flude 2015 Systematic review, not cancer-specific
McDougall 2001 Not a randomised controlled trial (RCT): secondary analysis of RCT with sub-group analysis of patients
with a self-reported diagnosis of cancer
McDougall 2011 Not a randomised controlled trial (RCT): secondary analysis of RCT with sub-group analysis of patients
with a self-reported diagnosis of cancer
Mehnert 2011 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Mendoza 2015 No response when contacted
Miki 2014 Proportion of patients currently receiving chemotherapy
Oh 2012 Proportion of patients currently receiving chemotherapy
Penedo 2003 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Peterson 2015 Proportion of patients undergoing active treatment
Poppelreuter 2008 Not a randomised controlled trial: two treatment groups were randomised; control group was not
Poppelreuter 2009 Not a randomised controlled trial: two treatment groups were randomised; control group was not
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Rea 2011 Unable to establish contact
Rottmann 2012 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Rummans 2006 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Schuurs 2013 Not a randomised controlled trial: participants were not randomly allocated to intervention and control
group
Singh 2014 No response from study authors
Srivastava 2015 Systematic review- no further new studies identified
Steindorf 2014 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Vadiraja 2009 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Weis 2009 Not an randomised trial: secondary analysis of randomised trial data
Weis 2011 Duplicate of Poppelreuter 2009
Winters-Stone 2011 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Winters-Stone 2013 Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Winters-Stone 2014a Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Winters-Stone 2014b Intervention not targeted at improving cognitive impairment or maintaining cognitive function
Wu 2014 Data not yet available
Characteristics of ongoing studies [ordered by study ID]
Cohen 2014
Trial name or title Effects of meditation on cognitive function and quality of life
Methods RCT
Participants Inclusion Criteria
Female breast cancer patients aged 35 to 60 years old, stage I-III who have undergone chemotherapy (either
neoadjuvant or adjuvant) 6 to 60 months prior to recruitment; who are currently undergoing hormone
therapy; who report cognitive impairment since starting chemotherapy as assessed by four questions of the
FACT-Cog; able to read and speak English, Spanish or Portuguese; who are all right-handed (for EEG analysis)
and willing to travel to one of two centres for meditation and assessment.
Exclusion Criteria
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Diagnosis of a formal thought disorder (e.g. schizophrenia) or neurological disorder known to affect cognitive
function; MMSE score of 23 or less; recurrent cancer; neurological/psychological disorder that may interfere
with ability to co-operate with study procedures; factors affecting fMRI and extreme mobility issues and
regular meditation practice (at least once a week for the last year)
Comparators
Wait-list controls
Non-cancer controls: Women with no history of cancer or prior chemotherapy. Exclusions; taking oestrogen
blockers or stimulators, extreme mobility issues or primary caretaker of a cancer patient
Country: USA
Interventions Definition: Tibetan Sound Meditation
Materials: CD and instructions for home practice
Duration: Twice weekly one-hour sessions over a 8-week period
Setting: Group-based setting
Personnel: Meditation instructor
Outcomes Assessments at baseline and 8 weeks later at end of the intervention period
Primary outcome
Cognitive function
Secondary outcomes
Mood, fatigue, QoL, memory and concentration
EEG and fMRI
Starting date October 2013
Contact information Lorenzo Cohen: lcohen@mdanderson.org
Notes Specific measures not reported
Damholdt 2013
Trial name or title Internet-delivered cognitive training for breast cancer survivors with cognitive complaints
Methods RCT
Participants Inclusion criteria
Forty years of age, disease-free breast cancer patients who have completed treatment with self-reported cog-
nitive impairment and access to the Internet
Exclusion criteria
Head trauma with loss of consciousness, neurological disease, severe physical or psychological disease, history
of drug or alcohol abuse, recurrence of breast cancer or a second cancer and where Danish is not their primary
language
Country: Denmark
Interventions Definition: Computerised cognitive training (Scientific Brain Training Pro)
Materials: Computer, Internet access
Duration: 40-60 minutes, 5 days a week for 6 weeks with weekly email reminders and motivational phone
calls
Setting: Home
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Comparator:Wait-list controls
Outcomes Assessments at baseline, 6 weeks (post-intervention) and 27 weeks later
Primary outcome
Paced Auditory Serial Addition Test
Measures of working memory and concentration
Secondary outcome
Cognitive Failures Questionnaire
Starting date Recruitment completed: data not yet available
Contact information Malene Flensborg: damholdmalenefd@psy.au.dk
Notes
Dhillon 2012
Trial name or title Cognitive rehabilitation for breast cancer survivors with perceived cognitive impairment
Methods RCT
Participants Inclusion criteria
At least 18 years of age with an invasive breast cancer diagnosis, surgery completed within 5 years and
completion of at least 3 cycles of chemotherapy 6 months previously (also radiotherapy completed 6 months
previously), self-reported cognitive function using the EORTC-CF subscale, current use of hormonal therapies
is permitted and English-language fluency
Exclusion criteria
ECOG status of more than 2, metastatic disease, major pre-existing neurological, psychiatric condition, co-
morbidity that would interfere with cognitive testing, previous cancer (with the exception of non-melanoma
skin cancer) and prior chemotherapy receipt
Country: Australia
Interventions Intervention one
Definition: Computerised cognitive training (Attention Process Training)
Materials: Computer programme, computer
Duration: 2-hour weekly sessions for 6 weeks
Setting: Group
Intervention two
Definition: Compensatory strategy training
Materials: None reported
Duration: 2-hour weekly sessions for 6 weeks
Setting: Group
Comparator:Wait-list control
Outcomes Measured at baseline, 4 weeks-, 6 months, and 12 months later
Primary outcome
Self-reported cognitive function (FACT-Cog cognitive impairment subscale)
Secondary outcomes
53Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dhillon 2012 (Continued)
Neuropsychological test battery (WRAT reading tests, COWAT, Thurstone WFT, Category animal fluency,
Trail Making Test A and B, WCST, Stroop test, WAIS digit symbol and digit span tests, Letter Number
Sequence, Spatial span, HVLT, BVMT, Grooved pegboard, Cogstate Neuropsychological Test, Functional
Impact Assessment)
QoL: FACT-G
Anxiety/depression: HADS
Fatigue: FACT-F
Starting date Not yet recruiting
Contact information Haryana Dhillion: haryana.dhillon@sydney.edu.au
Notes
Gokal 2012
Trial name or title Can physical activity enhance emotion, memory, attention and concentration in breast cancer patients re-
ceiving chemotherapy?
Methods RCT
Participants Inclusion criteria
Aged 18-75 years old, diagnosis of breast cancer (stages I-III) receiving chemotherapy and are able to speak
and read English
Exclusion criteria
Previously diagnosed with cancer, currently meeting 30 minutes of moderate intensity exercise 5 times a week,
breast cancer is a secondary diagnosis and a current psychiatric disorder
Country: United Kingdom
Interventions Definition: Physical activity (moderate intensity walking)
Materials: Booklet, pedometer, accelerometer
Duration: 12 weeks of 30 minutes, 5 times a week
Setting: Home-based
Comparator:Wait-list control
Outcomes Assessed at pre-intervention (mid-chemotherapy) and post-intervention (12 weeks later)
Primary outcomes
Neuropsychological test battery: Stroop test, WAIS digit span (forward and backward), Sustained Attention
to Response Task and WAIS block design. Self-reported cognitive function using the Cognitive Failures
Questionnaire
Secondary outcomes
HADS, Self-esteem questionnaire, Fatigue using the FACT-F, Emotional distress using the POMS
Starting date Trial completed: data not yet available
Contact information Kajal Gokal: k.gokal@lboro.ac.uk
Notes
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Trial name or title Memory and thinking skills workshop in improving cognitive rehabilitation in gynaecologic and breast cancer
survivors
Methods RCT
Participants Inclusion criteria
Prior curative treatment (including chemo-, radio- therapy and surgery) for gynaecological or breast cancer
at least 6 months previously, subjective concerns related to cancer and/or treatment, able to comprehend and
read English, able to provide consent and able to undergo consent, assessment and intervention sessions. For
a subset of participants able to undergo fMRI safety screening and fMRI assessments during study visits
Exclusion criteria
Currently ongoing curative treatment for cancer (including chemo-, radio- therapy and surgery); cancer onset
prior to age 21; unstable medical problems (e.g. heart disease); history of, or current symptoms of psychiatric
illnesses; current over-use or binging of alcohol within the past week; history of, or current neurological illness;
history of brain injury that significantly impacted cognition; history of CNS tumour; a score of 25 or more
on PHQ; a MMSE score of less than 26; a core of 45 or more on the Wender Utah Rating Scale for ADD
and for those undergoing MRI no medical or device issues that preventing imaging
Country: USA
Interventions Definition: Memory and skills workshop
Materials: None reported
Duration: Once weekly one-hour sessions for 8 weeks
Setting: Group
Comparator:Wait-list control
Outcomes Assessments at baseline and 7 weeks later
Primary outcome(s)
Cognitive function and QoL
Secondary outcome(s)
fMRI
Starting date Trial ongoing
Contact information Heidi Gray: hgray@uw.edu
Notes
Green
Trial name or title Randomized controlled trial comparing a web-based version of the Responding to Cognitive Concerns
(ReCog) cognitive-behavioural intervention to waitlist for subjective and objective cognitive functioning in
cancer survivors
Methods RCT
Participants Inclusion criteria
Adults aged 18 or more; experienced any adult-onset cancer (excluding cancer known to have affected the
CNS); completed all major treatments for cancer (e.g. surgery, chemotherapy, and radiotherapy) at least 6
months prior to data collection (but ongoing hormone treatments are acceptable); subjective complaints of
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Green (Continued)
cognitive impairment; access to a computer with a mouse and reliable Internet services
Exclusion criteria
Patients with cancer involving the CNS (primary or secondary tumours); previous treatment with cranial
radiotherapy or intrathecal chemotherapy; current cancer diagnosis
Country
Australia
Interventions Definition
Cognitive rehabilitation
Materials
Computer, Internet access
Delivery
One module per week (one hour) for four weeks
Setting
Web-delivered
Personnel
None
Outcomes Primary outcome
Objective cognitive function assessed by a series of 13 neuropsychological tests using the WebNeuro online
program
Subjective cognitive function assessed by the FACT-Cog, and the Brief Assessment of Prospective Memory
Secondary outcomes
Distress measured with the Kessler Psychological Distress scale, Illness perceptions assessed using the Brief
Illness Perceptions Questionnaire, Perceptions of Autonomy, assessed by the BPNS, Perceptions of Com-
petence, as measured by the Basic Psychological Needs Scale, Perceptions of Relatedness, as assessed by the
BPNS and QoL measured using the EORTC-QLQ-C30
Starting date Not yet recruiting
Contact information Heather Green: h.green@griffith.edu.au
Notes
Joly-Lobbedez 2013
Trial name or title Cancer and disorders of cognitive functions and QoL: “Cognitive rehabilitation in patients suffering from
cancer and treated with chemotherapy”
Methods RCT
Participants Inclusion criteria
Eighteen years and older with a solid or haematological tumour; between 1 month and 5 years since end of
chemotherapy and/or targeted therapy in the adjuvant or metastatic setting (ongoing Herceptin is permitted)
; absence of personality/psychiatric disorders; absence of brain metastases or primary brain tumour; absence
of analgesic treatment or opioid use; subjective cognitive complaints during or after treatment; provided
informed consent for the study and; fluency in the French language
Exclusion criteria
Primary CNS tumour or brain metastases, haematological malignancy, documented disorder of higher func-
56Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Joly-Lobbedez 2013 (Continued)
tions; psychiatric pathology; documented drug use; childhood-onset cancer; use of analgesic treatment and
opioids; alcohol consumption; participants unable to complete cognitive tests and refusal to participate
Country: France
Interventions Defintion: Computerised cognitive training using RehaCom @ software
Setting: Computer
Duration: Nine standardised cognitive rehabilitation sessions over a three-month period
Comparator group one: homework group completing 9 sessions of standardised exercise over the 3-month
period
Comparator group two: telephone follow-up (9 calls over the 3-month period)
Outcomes Assessments conducted at baseline and 3 months later (post-intervention)
Primary outcome
FACT-Cog
Secondary outcomes
QoL and objective cognitive neuropsychological tests
Starting date Recruitment ongoing
Contact information Florence Joly-Lobbedez: f.joly@baclesse.unicancer.fr
Notes
Kesler
Trial name or title Cognitive enhancement program in improving cognitive function in breast cancer survivors
Methods RCT
Participants Inclusion criteria
Diagnosed with breast cancer, completion of chemotherapy at least 1 year previously aged over 21 years old
Exclusion criteria
History of learning disability, head trauma, neurological disorder or significant psychiatric condition or
significant medical condition unrelated to cancer (e.g. diabetes), contraindications for MRI or pregnancy
Country: USA
Interventions Intervention one
Definition: Computer-based cognitive training (Lumiosity), compensatory strategy training and relaxation
Materials: Computer, Internet access
Duration: 20 minutes a day, 5 days a week for 6 weeks (cognitive training) and, 10 minutes a day for 6 week
(relaxation)
Setting: Home
Intervention two
Definition: Active journal writing, compensatory strategy training and relaxation
Materials: Diary or journal
Duration: 20 minutes a day, 5 days a week for 6 weeks (active journal writing) and, 10 minutes a day for 6
week (relaxation)
Setting: Home
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Kesler (Continued)
Intervention three
Definition: Computer-based cognitive training (Lumiosity)
Materials: Computer, Internet access
Duration: 20 minutes per day, 5 days a week for 6 weeks
Setting: Home
Outcomes Baseline and possibly 3 months post-intervention
Primary outcome
Standardised Executive Function Composite Score
Secondary outcome(s)
None reported
Starting date Study withdrawn as PI left institution
Contact information Shelli Kesler: skesler@standford.edu
Notes
Matthews 2007
Trial name or title The Activity Intervention for Chemobrain (TACTIC)
Methods RCT
Participants Inclusion criteria
Aged 18 years or older with non-metastatic cancer who has received at least 4 cycles of chemotherapy and
report persistent cognitive difficulties following treatment
Exclusion criteria
Have no prior diagnosis of CNS cancer, not have engaged in regular exercise (more than 20 minutes a day,
more than 5 days a week for at least 3 months), no cardiovascular disease or orthopaedic problems and no
major systemic diseases (e.g. liver)
Country: USA
Interventions Definition: Aerobic exercise
Materials: none reported
Duration: 6 months
Setting: none reported
Comparator: 6 compensatory strategies to aid memory and cognition
Outcomes Reported details indicate that trial is a cross-sectional studywith follow-up6months later at endof intervention
Primary outcome
Objective cognitive function using a neuropsychological test battery
Secondary outcome(s)
Psychological status, cardiorespiratory fitness and inflammatory biomarkers
Starting date Trial finished: will not share data
Contact information Charles Matthews: matthewsce@mail.nih.gov
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Matthews 2007 (Continued)
Notes
Myers
Trial name or title Emerging From the Haze™- Measuring the impact of a psycho-education program on perceived cognition
after breast cancer Treatment
Methods RCT
Participants Inclusion Criteria
Females (aged 18 years or older) who have completed treatment (chemotherapy with or without radiotherapy)
for stage 1 to 3 breast cancer between 2 and 24 months previously, FACT-Cog score less than 59 on the
PerceivedCognitive Impairment subscale and subjective complaint of cognitive concerns at time of enrolment,
must be able to understand and communicate proficiently in English and ability to provide written informed
consent and complete all study surveys
Exclusion Criteria
Patients with: a significant personality disorder or unstable psychiatric disorder (including active major de-
pression, substance abuse, psychosis or bipolar disorder); a known brain metastases, history of brain metas-
tases or radiation to the brain and; a history of stroke or other pre-existing neurological condition that may
contribute to cognitive dysfunction. Patients who are non-English speaker, receiving treatment for another
malignancy other than breast cancer and uncontrolled intercurrent illness including, but not limited to,
ongoing or active infection, chronic anaemia, uncontrolled hypothyroidism, symptomatic congestive heart
failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that
would limit compliance with study requirements
Country
USA
Interventions Definition
Psycho-education program
Materials
None reported
Duration
Weekly for two hours for 6 weeks in total
Setting
Clinic or via satellite
Comparator
Wait-list control
Personnel
Neuropsychologist
Outcomes Assessed at baseline and 6 weeks later following completion of the intervention
Primary
Self-reported cognitive function measured using the FACT-Cog
Starting date Currently recruiting
Contact information Charlotte Bailey: charlotte.bailey@cshs.org
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Myers (Continued)
Notes
Niedeggen 2009
Trial name or title Cognitive training to improve cognitive function following chemotherapy
Methods RCT
Participants Inclusion criteria
Patients who have completed chemotherapy 6 weeks ago
Exclusion criteria
Patients with neurological and psychiatric disorders or have not provided consent
Country: Germany
Interventions Definition: Cognitive training targeting concentration and memory problems
Materials: none reported
Duration: Weekly 45-minute sessions for 6 weeks (3 sessions on concentration and 3 sessions on memory)
Setting: not reported
Comparator:Wait-list control
Outcomes Assessments made at baseline and 7 weeks later (one week post-intervention)
Primary outcome
Objective cognitive function (Neuropsychological test battery)
Secondary outcomes
Subjective cognitive function and QoL
Starting date No response from author regarding trial status
Contact information Michael Niedeggen: niedegg@zedat.fu-berlin.de
Notes
Ryan 2010
Trial name or title Rehabilitation of cognitive changes in breast cancer survivors
Methods RCT
Participants Inclusion criteria
Female breast cancer patients (stages I-III), aged 18 to 70 years old who have completed chemotherapy 1 to
10 years previously, disease-free, English language fluency, demonstrable cognitive deficiency (1.0 SD below
normative values on at least one NP test during telephone screening or 1.0 SD below estimated pre-morbid
cognitive function and one of the pre-screen phone assessment measures) and computer skills sufficient to
use and upload data from the programme
Comparator: Family member or friend identified by the participant and has at least weekly contact with
participant
Exclusion criteria
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Ryan 2010 (Continued)
History of neurological disorder, traumatic brain injury or psychiatric disorder which may interfere with
cognitive testing, prior history or secondary diagnosis of cancer (with the exception of basal cell carcinoma or
melanoma treated with surgery only), prior chemotherapy receipt, evidence of recurrence, hearing or visual
deficit which impairs ability to use programme, unable to provide informed consent and male breast cancer
survivors
Country: USA
Interventions Definition: Computerised cognitive training (Cogmed)
Materials: Computer, computer programme
Duration: 30 minutes a day, 5 days a week for 5 weeks with weekly ’coach’ telephone calls
Setting: Home
Comparator: Attentional control: less difficult version of above software
Outcomes Assessments measured at baseline, 1 to 4 weeks post-intervention and 3 to 4 months post-intervention
Primary outcome
Objective working memory using neuropsychological test battery
Secondary outcome(s)
Self-reported functional status
Starting date No response from author regarding trial status
Contact information Elizabeth Ryan: ryane1@mskcc.org
Notes
Vardy 2009
Trial name or title Evaluation of a web-based cognitive rehabilitation programme in cancer survivors with self reported cognitive
impairment
Methods RCT
Participants Inclusion criteria
Diagnosis of a primary breast, colorectal or ovarian cancer with completion of a minimum of 3 cycles of
potentially curative chemotherapy within the last 6 to 60 months (completion of radio- or immuno- therapy
12 weeks prior to study enrolment), hormonal therapy is permitted if commenced at least 4 weeks prior to
randomisation, aged 18 years or older, male or female, self-reporting changes in memory and concentration,
English language fluency, able to give informed consent, access to computer and Internet and available for
intervention and follow-up
Exclusion criteria
ECOG Performance Status of > 2, evidence of recurrent or metastatic disease, history of, or active psychiatric,
cognitive or neurological or other disorder which may impact on cognitive testing, psychotropic medication
use is permitted if a stable routine has been established, any previous chemotherapy or cancer (with the
exception of non-melanoma skin cancer, cervical cancer in situ)
Interventions Definition: Computerised cognitive training and 30-minute telephone consultation teaching compensatory
strategies
Materials: Computer, Internet access
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Vardy 2009 (Continued)
Duration: Four-weekly 45-minute sessions per week for a total of 15 weeks
Setting: Home
Comparator: Treatment as usual (30-minute telephone consultation teaching compensatory strategies)
Outcomes Assessments taken at baseline, post-intervention and 6 months post-intervention
Primary outcome
Self-reported cognitive function as assessed by the Functional Assessment of Cancer Therapy - Cognitive
Function (FACT-COG)
Secondary outcomes
Objective cognitive function as assessed by the CogState battery of tests (memory, attention and decision
making). Depression/Anxiety as assessed by the General Health Questionnaire (GHQ); Fatigue as assessed
by FACT-F; QoL as assessed by the FACT-G and; Stress as assessed by the PSS
Starting date Trial closed- data not yet available
Contact information Victoria Bray: victoria.bray2@sswhas.nsw.gov.au
Notes
Abbreviations: ADD = Attention Deficit Disorder; BPNS = basic Psychological Needs Survey; BVMT = Brief Visuospatial Memory
Test; CD = Compact Disc; CNS = Central Nervous System; COWAT = Controlled Oral Word Association Test; ECOG = Eastern
Cooperative Oncology Group; EEG = electroencephalogram; EORTC-CF = European Organisation for Research and Treatment
for Cancer- Cognitive Function subscale; EORTC-QLQ-C30 = European Organisation for Research and Treatment for Cancer-
Quality of Life Questionnaire; FACT-Cog = Functional Assessment of Cancer Therapy- Cognition subscale; FACT-F = Functional
Assessment of Cancer Therapy-Fatigue subscale; FACT-G = Functional Assessment of Cancer Therapy-General scale; fMRI =
functional Magnetic Resonance Imaging; HADS = Hospital Anxiety Depression Scale; HVLT-R = Hopkin’s Verbal Learning Test-
Revised; MMSE = Mini-Mental Status Examination; PSS = Perceived Stress Scale; PHQ = Patient Health Questionnaire; POMS
= Profile of Mood State; QoL = quality of life; RCT = Randomised Controlled Trial; SD = Standard Deviation; WAIS = Wechsler
Adult Intelligence; WCST = Wisconsin Card Sorting Test; WFT = Word Fluency Test; WRAT = Wide Range Achievement Test
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D A T A A N D A N A L Y S E S
Comparison 1. Compensatory strategy training versus wait-list control immediately post-intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Physical well-being 2 95 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.59, 0.83]
2 Psychological well-being 2 95 Std. Mean Difference (IV, Random, 95% CI) -0.57 [-0.98, -0.16]
Comparison 2. Compensatory strategy training versus wait-list control 2-months post-intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Physical well-being 2 95 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.89, 0.47]
2 Psychological well-being 2 95 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-1.10, 0.34]
Analysis 1.1. Comparison 1 Compensatory strategy training versus wait-list control immediately post-
intervention, Outcome 1 Physical well-being.
Review: Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment
Comparison: 1 Compensatory strategy training versus wait-list control immediately post-intervention
Outcome: 1 Physical well-being
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ferguson 2012 19 7.59 (1.82) 21 8.01 (1.32) 47.5 % -0.26 [ -0.88, 0.36 ]
Von Ah 2012 26 45.71 (5.98) 29 43.18 (4.72) 52.5 % 0.47 [ -0.07, 1.00 ]
Total (95% CI) 45 50 100.0 % 0.12 [ -0.59, 0.83 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 3.00, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [control] Favours [intervention]
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Analysis 1.2. Comparison 1 Compensatory strategy training versus wait-list control immediately post-
intervention, Outcome 2 Psychological well-being.
Review: Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment
Comparison: 1 Compensatory strategy training versus wait-list control immediately post-intervention
Outcome: 2 Psychological well-being
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ferguson 2012 19 5.63 (1.35) 21 6.51 (1.2) 41.4 % -0.68 [ -1.32, -0.04 ]
Von Ah 2012 26 45.33 (5.98) 29 48.09 (5.03) 58.6 % -0.49 [ -1.03, 0.04 ]
Total (95% CI) 45 50 100.0 % -0.57 [ -0.98, -0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0066)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [control] Favours [intervention]
Analysis 2.1. Comparison 2 Compensatory strategy training versus wait-list control 2-months post-
intervention, Outcome 1 Physical well-being.
Review: Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment
Comparison: 2 Compensatory strategy training versus wait-list control 2-months post-intervention
Outcome: 1 Physical well-being
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ferguson 2012 19 7.04 (1.79) 21 7.91 (1.1) 46.7 % -0.58 [ -1.22, 0.05 ]
Von Ah 2012 26 45.03 (6.17) 29 44.49 (2.81) 53.3 % 0.11 [ -0.42, 0.64 ]
Total (95% CI) 45 50 100.0 % -0.21 [ -0.89, 0.47 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 2.71, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [control] Favours [intervention]
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Analysis 2.2. Comparison 2 Compensatory strategy training versus wait-list control 2-months post-
intervention, Outcome 2 Psychological well-being.
Review: Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment
Comparison: 2 Compensatory strategy training versus wait-list control 2-months post-intervention
Outcome: 2 Psychological well-being
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ferguson 2012 19 5.37 (1.22) 21 6.4 (1.38) 46.7 % -0.77 [ -1.42, -0.13 ]
Von Ah 2012 26 44.91 (6.82) 29 45.11 (5.13) 53.3 % -0.03 [ -0.56, 0.50 ]
Total (95% CI) 45 50 100.0 % -0.38 [ -1.10, 0.34 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [control] Favours [intervention]
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Neoplasms] explode all trees
#2 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan* or leukemia* or leukaemia*) .mp
#3 #1 or #2
#4 MeSH descriptor: [Cognition Disorders] explode all trees
#5 MeSH descriptor: [Neurobehavioral Manifestations] explode all trees
#6 MeSH descriptor: [Mental Processes] explode all trees
#7 MeSH descriptor: [Neuropsychological Tests] explode all trees
#8 MeSH descriptor: [Attention] explode all trees
#9 (chemo* near/5 (fog or brain))
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#10 ((cognit* or neurocognit* or neuropsycholog* or memory or neurobehavior* or neurobehaviour* or problem solving or attention
or concentrat*) adj5 (deficit* or declin* or disorder* or function* or dysfunction* or impair* or decrement* or disturb* or problem* or
sequelae*))
#11 #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 #3 and #11
Appendix 2. MEDLINE search strategy
1 exp Neoplasms/
2 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan* or leukemia* or leukaemia*).mp
3 1 or 2
4 exp Cognition Disorders/
5 exp Neurobehavioral Manifestations/
6 exp Mental Processes/
7 exp Neuropsychological Tests/
8 Attention/
9 (chemo* adj5 (fog or brain)).mp.
10 ((cognit* or neurocognit* or neuropsycholog* ormemory or neurobehavior* or neurobehaviour* or problem solving or attention
or concentrat*) adj5 (deficit* or declin* or disorder* or function* or dysfunction* or impair* or decrement* or disturb* or
problem* or sequelae*)).mp
11 4 or 5 or 6 or 7 or 8 or 9 or 10
12 3 and 11
13 randomized controlled trial.pt.
14 controlled clinical trial.pt.
15 randomized.ab.
16 placebo.ab.
17 clinical trials as topic.sh.
18 randomly.ab.
19 trial.ti.
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(Continued)
20 13 or 14 or 15 or 16 or 17 or 18 or 19
21 12 and 20
22 exp animals/ not humans.sh.
23 21 not 22
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
pt=publication type
ab=abstract
ti=title
Appendix 3. Embase search strategy
1 exp neoplasm/
2 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan* or leukemia* or leukaemia*).mp.
3 1 or 2
4 exp cognitive defect/
5 cognition/
6 neuropsychological test/
7 attention/
8 (chemo* adj5 (fog or brain)).mp.
9 ((cognit* or neurocognit* or neuropsycholog* or memory or neurobehavior* or neurobehaviour* or problem solving or attention or
concentrat*) adj5 (deficit* or declin* or disorder* or function* or dysfunction* or impair* or decrement* or disturb* or problem* or
sequelae*)).mp.
10 4 or 5 or 6 or 7 or 8 or 9
11 3 and 10
12 crossover procedure/
13 double-blind procedure/
14 randomized controlled trial/
15 single-blind procedure/
16 random*.mp.
17 factorial*.mp.
18 (crossover* or cross over* or cross-over*).mp.
19 placebo*.mp.
20 (double* adj blind*).mp.
21 (singl* adj blind*).mp.
22 assign*.mp.
23 allocat*.mp.
24 volunteer*.mp.
25 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26 11 and 25
key: [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drugmanufacturer, device
trade name, keyword]
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Appendix 4. PsycINFO search strategy
1 exp neoplasms/
(cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan* or leukemia* or leukaemia*).mp.
3 1 or 2
4 cognitive impairment/
5 exp cognitive processes/
6 exp neuropsychological assessment/
7 attention/
8 (chemo* adj5 (fog or brain)).mp.
9 ((cognit* or neurocognit* or neuropsycholog* or memory or neurobehavior* or neurobehaviour* or problem solving or attention or
concentrat*) adj5 (deficit* or declin* or disorder* or function* or dysfunction* or impair* or decrement* or disturb* or problem* or
sequelae*)).mp.
10 4 or 5 or 6 or 7 or 8 or 9
11 3 and 10
12 clinical trials/
13 (random* or trial* or crossover* or cross over* or double blind or single blind or placebo* or assign* or allocat*).mp.
14 12 or 13
15 11 and 14
Appendix 5. CINAHL search strategy
S1 (MH “Neoplasms+”)
S2 “cancer*”
S3 “neoplas*”
S4 “tumor*”
S5 “tumour*”
S6 “carcinoma*”
S7 “adenocarcinoma*”
S8 “malignan*”
S9 “leukemia*”
S10 “leukaemia*”
S11 (S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10)
S12 S1 or S11
S13 (MH “Cognition Disorders+”)
S14 (MH “Neurobehavioral Manifestations+”)
S15 (MH “Mental Processes+”)
S16 (MH “Neuropsychological Tests+”)
S17 (MH “Attention+”)
S18 “chemo*”
S19 “fog”
S20 “brain”
S21 (S19 or S20)
S22 (S18 N2 S21)
S23 “cognit*”
S24 “neurocognit*”
S25 “neuropsycholog*”
S26 “memory”
S27 “neurobehavior*”
S28 “neurobehaviour*”
S29 “problem solving”
S30 “attention”
S31 “concentrat*”
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S32 (S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30)
S33 “deficit*”
S34 “declin*”
S35 “disorder*”
S36 “function*”
S37 “dysfunction*”
S38 “impair*”
S39 “decrement*”
S40 “disturb*”
S41 “problem*”
S42 “sequelae*”
S43 (S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42)
S44 (S32 N2 S43)
S45 (S13 or S14 or S15 or S16 or S17 or S22 or S44)
S46 (S12 and S45)
S47 MH “Randomized controlled trials”
S48MH “Clinical trials”
S49 MH “Placebos”
S50 (S47 or S48 or S49)
S51 (S44 and S50)
Appendix 6. PubMed search strategy
#1 neoplasm*[MeSH Terms]
#2 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan* or leukemia* or leukaemia*)
#3 #1 or #2
#4 cognition disorders[MeSH Terms]
#5 neurobehavioral manifestations[MeSH Terms]
#6 mental processes[MeSH Terms]
#7 neuropsychological tests[MeSH Terms]
#8 attention[MeSH Terms]
#9 “chemo* fog”
#10 “chemo* brain”
#11 ((((((((“cognit* deficit*”) OR “cognit* declin*”) OR “cognit* disorder*”) OR “cognit* function*”) OR “cognit* dysfunction*”)
OR “cognit* impair*”) OR “cognit* decrement*”) OR “cognit* problem*”) OR “cognit* sequelae*”
#12 ((((((((“memory deficit*”) OR “memory declin*”) OR “ memory disorder*”) OR “ memory function*”) OR “ memory dysfunc-
tion*”) OR “memory impair*”) OR “memory decrement*”) OR “ memory problem*”) OR “memory sequelae*”
#13 ((((((((“neurobehavior* deficit*”) OR “neurobehavior* declin*”)OR “neurobehavior* disorder*”) OR “neurobehavior * function*”)
OR “neurobehavior* dysfunction*”) OR “neurobehavior* impair*”) OR “neurobehavior* decrement*”) OR “neurobehavior* prob-
lem*”) OR “neurobehavior* sequelae*”
#14 ((((((((“neurobehaviour* deficit*”) OR “neurobehaviour* declin*”) OR “neurobehaviour* disorder*”) OR “ neurobehaviour *
function*”) OR “neurobehaviour* dysfunction*”) OR “neurobehaviour* impair*“) OR “neurobehaviour* decrement*”) OR “neurobe-
haviour* problem*”) OR “neurobehaviour* sequelae*”
#15 ((((((((“problem solving deficit*”) OR “problem solving declin*“) OR ”problem solving disorder*“) OR ”problem solving func-
tion*“) OR ”problem solving dysfunction*“) OR ”problem solving impair*“) OR ”problem solving decrement*“) OR ”problem solving
problem*“) OR ”problem solving sequelae*“
#16 ((((((((”attention deficit*“) OR ”attention declin*“) OR ”attention disorder*“) OR ”attention function*“) OR ”attention dysfunc-
tion*“) OR ”attention impair*“) OR ”attention decrement*“) OR ”attention problem*“) OR ”attention sequelae*“
#17 ((((((((”concentrat* deficit*“) OR ”concentrate*“) OR ”concentrat disorder*“) OR ”concentrat function*“) OR ”concentrat dys-
function*“) OR ”concentrat impair*“) OR ”concentrat decrement*“) OR ”concentrat problem*“) OR ”concentrat sequelae*“
#18 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
#19 #3 and #17
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#20randomized controlled trial[pt]
#21 controlled clinical trial[pt]
#22 randomized[tiab]
#23 placebo[tiab]
#24 clinical trials as topic[mesh:noexp]
#25 randomly[tiab]
#26 #20 or #21 or #22 or #23 or #24
#27 animals [mh] NOT humans [mh]
#28 #26 NOT #27
#29 #19 AND #28
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